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ABSTRACT
RADICAL CATIONS IN SYNTHESIS: UTILIZING AN ELECTRON
TRANSFER-INITIATED CYCLIZATION TOWARD THE NATURAL
PRODUCT APICULAREN A
Alexander J. Poniatowski, PhD
University of Pittsburgh, 2009
Reported herein is a synthetic campaign toward the vacuolar ATPase inhibitor apicularen
A through an oxidative cyclization protocol. In this protocol (termed Electron Transfer-
Initiated Cyclization, or ETIC), highly reactive oxocarbenium ions are generated through
benzylic carbon–carbon σ-bond cleavage under chemically mild conditions. Regioselective
cleavage of one homobenzylic ether in the presence of another homobenzylic ether is achieved
by selectively weakening one carbon–carbon σ-bond through substitution. This work demon-
strates that if bond cleavage is sufficiently rapid following oxidation, then oxidative fragmen-
tation reactions can be used to generate stable cations selectively in the presence of other
readily oxidized functional groups
iv
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1.0 APICULAREN A
It is our goal to develop a synthetic route to apicularen A (1, Figure 1). Our route will
utilize an electron transfer initiated cyclization (ETIC) reaction1 as a key synthetic step,
demonstrating the relevance of this method to total synthesis. With the complex architecture
of apicularen A as a proving ground, we will apply ETIC technology in a powerful and
unprecedented fashion.
Figure 1: (−)-Apicularens A and B
1.1 BACKGROUND AND BIOLOGICAL PROFILE
The apicularens (Figure 1) are natural products isolated2 from the myxo-bacterial genus
Chondromyces. According to bacterial feeding experiments by Jansen and coworkers,3 the
framework is biosynethesized almost exclusively from acetate, with glycine as a precursor
for the enamide side-chain (C17, C18 and N), and C25 originating from methionine. This
1
class of molecule has been shown to possess potent cytotoxic activity with IC50 values in the
0.23–6.8 nM range against nine human cancer cell lines.2;3 The cytotoxicity of apicularen A
has been attributed to its function as a vacuolar ATPase (or V-ATPase) inhibitor.
1.1.1 Vacuolar ATPases
Primary ion pumps consume ATP to facilitate ion transport across cell membranes. These
proteins are highly evolutionarily conserved, found in all eukaryotic cells and tissures.4;5;6
There are three types of ATPases7 and a “superfamily” of ATP-Binding Cassette (ABC)
transporters.8 The P-ATPases involve a phosphorylated transition state, the F-ATPases
function primarily in ATP synthesis, and the V-ATPases function only in ATP breakdown
in order to move protons across cell membranes. The ABC transporters consume ATP to
effect the uptake of a variety of solutes.
Malfunction of V-ATPase behavior has been implicated as the cause of the human dis-
eases osteoporosis,9 distal renal tubular acidosis,10 and sensorineural deafness.10 Further-
more, the diseases suspected of V-ATPase involvement include diabetes,11 Alzheimer’s,12
Parkinson’s,13 cardiovascular disorders,14 and glaucoma.15
1.1.2 Vacuolar ATPase Inhibitors
Known V-ATPase inhibitors fall generally into four structural classes: 1) macrolide lactones,
2) conjugated aromatics, 3) salicylate enamides, and 4) macrolide lactams.
1.1.2.1 Macrolide Lactones The earliest known V-ATPase inhibitors are the con-
canamycins (1982) and bafilomycins (1984), while the archazolids are a more recent dis-
covery (2003). These compounds proved valuable tools for distinguishing among the three
different types of ATPases.16 Representative compounds from the macrolide lactone class
of V-ATPase inhibitor (shown in Figure 2) include concanamycin B17 (2, IC50 = 5 nM),
bafilomycin A18 (3, IC50 = 2 nM), and archazolid A
19 (4, IC50 ≈ 40 nM).
2
Figure 2: Macrolide lactone V-ATPase inhibitors
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1.1.2.2 Conjugated Aromatics The second class of V-ATPase inhibitor discovered was
the extended pi-system aromatics, first seen in the compound diphyllin20 (5a, IC50 = 17 nM).
The Fujisawa Pharmaceutical Company compounds FR17799521 (5b, IC50 = 460 nM) and
FR20212622 (5c, IC50 = 99 nM) also fall into this structural category (Figure 3).
Figure 3: Conjugated aromatic V-ATPase inhibitors
1.1.2.3 Salicylate Enamides The salicylate enamide class of V-ATPase inhibitors in-
cludes the apicularens, as well as the closely related salicylihalamides, lobatamides, and
oximidines. Figure 4 includes representative members salicylihalamide A23 (6, GI50 = 15
nM against the NCI 60-cell human tumor assay), lobatamide A24 (7, GI50 ≈ 9 nM against the
NCI 60-cell human tumor assay), and oximidine I25 (8, IC50 = 16–740 nM against normal
and transformed rat 3Y1 fibroblasts).
1.1.2.4 Macrolide Lactams The final structural class of V-ATPase inhibitor is the
macrolide lactams, the only presently-known members of which are the chondropsins.26
Chondropsin A (9, IC50 = 1 nM) is shown in Figure 5.
4
Figure 4: Salicylate enamide V-ATPase inhibitors
Figure 5: Macrolide lactam V-ATPase inhibitor
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1.2 PREVIOUS APICULAREN SYNTHESES
Apicularen A (1, Figure 1) has attracted attention from the synthetic community. This
section will review previous reports of synthetic work toward apicularen A.
1.2.1 De Brabander’s Total Synthesis
De Brabander and co-workers27;28 completed the first total synthesis of apicularen A. Their
route (Figure 6) utilized an asymmetric hetero-Diels-Alder annulation of 163 and Danishef-
sky’s diene 10 catalyzed by Jacobsen’s chromium catalyst29 11 to furnish 12. Subsequent
1,4 addition of a vinyl cuprate, NaBH4 reduction and silyl ether formation produced 13.
Hydroboration/oxidation, then asymmetric Brown allylation (dr = 77:23 in favor of the
9,11-anti-, 13,15-syn diastereomer) supplied 14. Macrolactonization was effected by treat-
ment of 14 with NaH in THF to procure 15. At this point the authors have accessed the
apicularen A core, and their work on the side chain follows. A second silyl ether forma-
tion was performed, followed by OsO4 dihydroxylation and successive oxidative cleavage to
generate aldehyde 16. Horner-Emmons coupling with allyl diethylphosphonoacetate and
sequential Pd-catalyzed ester removal yielded carboxylic acid 17. The epimers (differing
at C11) were separated. The carboxylic acid was converted to the acyl azide, which was
in turn transformed into the derivative isocyanate. Alkylation with lithiated 1-bromo-1,3-
hexadiene followed by deprotection of both alcohols afforded apicularen A. Overall, the De
Brabander synthesis involves 17 linear steps. The chiral induction steps in the sequence
are the chromium-catalyzed asymmetric Diels-Alder annulation (C9), the diastereoselective
Michael addition (C13), the stoichiometric Brown allylation (C15), and separation of epimers
differing at C11. The side chain was installed via a vinyl copper addition to an isocyanate.
1.2.2 Taylor’s Formal Synthesis
Taylor and co-workers reported a formal synthesis of (+)-apicularen A30 (Figure 7). Tri-
flate 19 (from d-glucal) was used in a Grignard addition with 18 to yield intermediate 20.
Benzofuran 20 was subjected to ozonolytic conditions with acetyl salicylaldehyde 21 as the
6
Figure 6: De Brabander’s route to (−)-apicularen A
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result. Oxidation of the aldehyde to a carboxylic acid, methanolysis of the acetate, and
methylation of both the free phenol and carboxylic acid produced 22. Diastereoselective al-
lylation of hemiacetal 22 (a single diastereomer was observed) followed by complete removal
of the TBDPS group with TBAF, then TBS re-protection of the secondary alcohol provided
23. Ozonolysis of terminal olefin 23 and serial Brown allylation gave 24, which was cyclized
using DCC/DMAP to lactone 25. Conversion of methyl ether 25 to the corresponding TBS
ether was necessary to claim a formal synthesis, since 26 is a known intermediate from De
Brabander’s work. The Taylor synthesis involved 17 linear steps from naturally occurring
d-glucal to known intermediate 26 (which by De Brabander’s work is itself five steps re-
moved from apicularen), with the stereochemical configuration at C9 and C11 deriving from
d-glucal, C13 being controlled diastereoselectively by the allylation at the anomeric carbon
of 22, and C15 being established by a stoichiometric Brown allylation.
Figure 7: Taylor’s route to (+)-apicularen A
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1.2.3 Nicolaou’s Total Synthesis
The Nicolaou group completed a total synthesis of apicularen A31 (Figure 8) which the au-
thors claim was “inspired by its polyacetate-based biosynthesis.” The route relies heavily
on an iterative allylation/ozonolysis sequence to mimic nature’s use of two-carbon acetate
building blocks to construct intermediate 31. Intermediate 31 was converted to vinyl io-
dide 32 under Takai’s conditions, and coupling with amide 33 using Rb2CO3 and copper(I)
thiophene-2-carboxylate produced 34. Lactonization using NaH followed by deprotection
completed Nicolaou’s synthesis of 1, totaling 18 linear steps from known starting material.
The chiral induction steps for this synthesis: (−)-Ipc Brown allylation, C9; (+)-Ipc Brown
allylation, C11; substrate controlled diastereoselective allylations, C13; (+)-Ipc Brown ally-
lation, C15. The side chain was appended through Rb/Cu-mediated C–N bond formation
between an amide and a vinyl iodide.
1.2.4 Rychnovsky’s Formal Synthesis
Rychnovsky’s synthesis32 (Figure 9) takes a more convergent approach to apicularen. Cou-
pling nitrile 35 and iodide 36 in a highly diastereoselective manner followed by lithium
ammonia reduction yielded protected polyol 37. Oxidative cyclization and subsequent con-
version of the hemiacetal to mixed acetal using DOWEX resin and MeOH followed by
secondary alcohol protection provided 38. To the anomeric carbon of 38 was added 2,4-
pentadienyl-trimethylsilane, introducing the diene moiety for an impressive intramolecular
Diels-Alder annulation. Otera esterification between 39 and methyl 3-bromopropynylate
delivered the dienophilic fragment, and addition of DDQ, methanolysis, and TBS etherifi-
cation produced arene 41 in a 44% yield (from 39). To complete their formal synthesis,
the authors converted the bromide to a phenol by treatment of 41 with n-BuLi/(TMSO)2,
and protected the phenol as the acetate. The TMS group was converted to an iodide with
NIS, and the acetate and TBS groups were removed with K2CO3/MeOH then DOWEX /
MeOH. The authors attempted to couple the resulting vinyl iodide with amide 33 (anal-
ogous to the Nicolaou route), but had no success. To complete a formal synthesis, the
vinyl iodide was reduced with Bu3SnH/AIBN to supply terminal olefin 42, a known in-
9
Figure 8: Nicolaou’s route to (−)-apicularen A
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termediate in previous apicularen A syntheses. The Rychnovsky synthesis of apicularen A
involves 20 synthetic steps (17 at its longest linear sequence) to arrive at intermediate 42,
which is itself 10 steps from apicularen A by De Brabander’s methods. The chiral induction
steps in Rychnovsky’s paper are: substrate controlled diastereoselective anomeric addition
of 2,4-pentadienyl-trimethylsilane (C9), a Ru-(R)-(+)-BINAP catalyzed Noyroi β-ketoester
reduction (C11), the substrate controlled diastereoselective nirile/iodide coupling (C13), and
chiral pool reactant (S)-epichlorohydrin (C15).
Figure 9: Rychnovsky’s route to (−)-apicularen A
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1.2.5 Panek’s Total Synthesis
The Panek group completed a total synthesis of apicularen A33 (Figure 10). Their route
used a [4+2] annulation of aldehyde 43 and allylsilane 44 to yield 45. Protecting group
manipulations, followed by epoxidation, epoxide opening with DIBAL, and Mitsunobu in-
version of the configurationally incorrect secondary alcohol led to intermediate 46. Further
protecting group manipulation, primary alcohol oxidation to an aldehyde, one-carbon ho-
mologation of the resulting aldehyde, (+)-Ipc Brown allylation of the homologated aldehyde
47, more protecting group manipulation and formation of an activated cyanomethyl ester
produced intermediate 48. This is the lone example in the apicularen literature of this type
of activated benzoate ester to effect lactonization, which proceeded in 63% yield. Lactone
49 was treated with OsO4, then NaIO4, and the resulting aldehyde was converted to a vinyl
iodide using Takai’s conditions. As in the Nicolaou route, the amide side chain was appended
under Rb/CuTC coupling conditions. The Panek synthesis completed apicularen A in 29
synthetic steps, with the stereocenters having been set by an asymmetric [4+2] annulation
of an aldehyde and chiral allyl silane (C9 and C13), a substrate controlled (and incorrect)
epoxidation and subsequent Mitsunobu inversion (C11), and (+)-Ipc Brown allylation (C15).
The side chain was appended in a manner virtually identical to the Nicolaou report.
1.2.6 Rizzacasa’s Formal Synthesis
The Rizzacasa group reported a formal synthesis of apicularen A.34 In one of the more con-
vergent apicularen syntheses, bromide 51 and stannane 50 (Figure 11) were coupled under
Stille conditions. Efficient macrolactonization using NaH, followed by TBAF desilylation,
and MnO2 allylic oxidation produced enone 53. They key step in the route was a transannu-
lar etherification accomplished using Amberlyst-15 acidic resin in refluxing CDCl3 to secure
54. Notably, stereoisomers differing at C9 and C13 were shown to equilibrate to the absolute
stereochemical configuration of the natural product. This demonstrates that the epimeriza-
tion is under thermodynamic control, and the only stereocenter requiring an asymmetric
reagent/reactant to control its absolute configuration is C15. Sodium borohydride reduction
gave a 1:1 mixture of epimers at C11, and after separation of the diastereomers and methyl
12
Figure 10: Panek’s route to (−)-apicularen A
13
ether removal, the known intermediate 42 was accessed to complete the formal synthesis.
The Rizzacasa synthesis used 15 synthetic steps from known material to arrive at 42, which
is itself 10 steps removed from apicularen A (by De Brabander’s work). The sources of ab-
solute stereocontrol: (+)-Ipc Brown allylation (C15) which in turn influences both C9 and
C13, and a separation of epimers differing at C11.
Figure 11: Rizzacasa’s route to (−)-apicularen A
1.2.7 Maier’s Total Synthesis
The Maier synthesis of apicularen A35 was also convergent, and shares several themes with
the Rizzacasa route. Triflate 55 and stannane 56 (Figure 12) were coupled using a Stille
reaction, protecting group manipulation and installation of the mixed-acetal carboxylate
provided 58, which cyclized to give the macrolactone 59. The key transannular etherifica-
tion was accomplished through an oxy-mercuration, and subsequent reduction of the alkyl
mercury to the alkane produced 60. Further protecting group manipulation accessed alde-
hyde 61, which was coupled with amide 33 to form acyl hemiaminal 62. The hemiaminal
was O-acylated and acetic acid was eliminated to secure 63. Removal of the silyl protecting
groups with tris(dimethyl-amino)sulfonium difluorotrimethylsilicate yielded apicularen A 1.
The Maier synthesis arrived at apicularen A in 24 synthetic steps. The chiral induction steps
14
were a substrate controlled oxy-mercuration (C9), chiral pool reactants (C11 and C15), and
a substrate-controlled diastereoselective oxidation of a dithiane (C13). The side chain was
appended by coupling an aldehyde with an amide to give an acyl hemiaminal, which was
then O-acylated; elimination of acetic acid provided the enamide functional group.
Figure 12: Maier’s route to (−)-apicularen A
15
1.2.8 O’Doherty’s Formal Synthesis
The most recent report involving synthetic studies of apicularen is from the O’Doherty
group.36 Like the Rizzacasa and Maier routes before it, the O’Doherty route is centered
around a transannular etherification reaction strategy. The formal synthesis begins with the
isomerization of alkynoate 64 to dieneoate 65, followed by an asymmetric dihydroxylation to
establish the first chiral center of the synthesis (C15 of apicularen). Trapping the resulting
diol as the cyclic carbonate led to intermediate 66, which was in turn converted to δ-hydroxy
enoate 67. The configuration at C13 was set by treating the hemiacetal that results from
67 and benzaldehyde with KOt-Bu. The carboxylate was elaborated and the desired con-
figuration at C11 was established via an substrate-controlled diastereoselective allylation to
provide 69. Grubbs cross metathesis of 69 with styrene 70 led to the disubstituted E-styrene,
which, when deprotected, produced 71. The macrolactone was formed by subjecting 71 to
Yamaguchi’s conditions, and the product 59 is the substrate required for the key transan-
nular etherification reaction. When 59 was treated with KOt-Bu in THF at 0 ◦C, the only
observed diastereomer was the desired tetrahydropyran 60. This significant finding lends
a useful method to the apicularen literature, which compliments the existing transannular
etherification methods. Furthermore, O’Doherty’s report reinforces Rizzacasa’s finding that
there is an certain tendency to form the naturally occurring diastereomer of apicularen A
through a transannular etherification. The O’Doherty route involves 21 synthetic steps from
commercially available starting materials, and 18 steps at its longest linear sequence.
16
Figure 13: O’Doherty’s route to (−)-apicularen A
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2.0 PROPOSED ROUTE TO APICULAREN A
2.1 OUR PLANNED SYNTHESIS
We hypothesized that the tetrahydropyran ring of apicularen could be constructed using
an electron transfer-initiated cyclization (ETIC) reaction, where a pendant enol acetate nu-
cleophile attacks an oxocarbenium ion formed within the 10-membered apicularen lactone
(Figure 14, lactone ring abbreviated for clarity). We further hypothesized that a measure of
diastereoselectivity could be achieved in an ETIC reaction, due to the following considera-
tions: 1) if an oxocarbenium ion can be formed within the ring, the E geometry is predicted
(that is, k1 > k−1, not only because this orients the R groups trans to one another rather than
cis as in the Z configuration, but also because the E configuration is expected to produce
less added strain to the ten-membered ring than the Z configuration, and 2) we suppose that
the transition state energies mimic the energies of the respective products. Figure 14 depicts
the THP formation occurring through a six membered chair-type transition state wherein
the presence of the lactone ring should allow for a measure of facial selectivity, as the elec-
trophile has but one face exposed to attack in either conformation. With these hypotheses,
we undertook a synthetic campaign toward apicularen A. We will incorporate convergency
in our route, as the existing routes to apicularen A in the chemical literature are largely
linear synthetic sequences.
In our initial retrosynthetic analysis (Figure 15), a six membered ring was imagined to
be formed via ETIC chemistry, using an established ten-membered ring to establish rigidity,
allowing for stereocontrol. An attractive advantage to an ETIC to construct carbon-carbon
bonds is that a highly electrophilic oxocarbenium ion is generated under mild chemical
conditions; strongly acidic or basic conditions are not required. This presents an opportunity
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Figure 14: Envisioned THP ring formation (lactone ring abbreviated for clarity)
to chemoselectively access two different oxocarbenium ions. In the first instance, the acetal
is ionized under traditional Lewis acidic conditions, and the resulting oxocarbenium ion
attacked by a suitable external three-carbon nucleophile (in this example, introducing a
propargyl group). In the second instance, an oxocarbenium ion is generated under chemically
mild oxidizing conditions to form an oxocarbenium ion that is subsequently trapped by intra-
molecular delivery of a carbon nucleophile (in this example, an enol acetate) resulting in a
six membered ring. The orthogonality of these methods allows for these electrophiles to be
unmasked in a chemoselective manner.
Our proposed route to apicularen is shown in the forward direction in Figure 16. Known
ester 11637 could be reduced to aldehyde 117. The diol portion of key acetal intermediate 72
could be prepared by asymmetric allylation of known aldehyde 121, followed by epoxidation
to yield 133. Grignard addition to epoxide 133 could lead to diol 166, which could be
converted to the bis-TMS ether derivative for use in a Noyori acetal synthesis38 to produce
acetal 72. Addition of a propargyl group to the acetal center of 72 could yield doubly-
secondary ether 73, which could undergo hydrolysis, lactonization, and conversion to enol
acetate 74. ETIC substrate 74 could undergo cyclization to tetrahydropyrone 75. An
epimerization inspired by Rizzacasa’a work34 could be applied to synthesize 54 and achieve
a formal synthesis of the natural product. One advantage to our proposed route include
a measure of convergency by rapidly establishing molecular complexity through coupling
aldehyde 117 and diol 166. The major advantage to our proposed route is the fact that the
sequence is short; a formal synthesis of apicularen would be achieved in 12 synthetic steps
from known compounds 116 and 121.
The proposed mechanism for the ETIC reaction (Figure 17), involves coordination of
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Figure 15: Initial retrosynthetic analysis
20
Figure 16: Proposed route to apicularen A
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CeIV to the dimethyl-p-methoxy benzyl arene, followed by an inner-sphere electron transfer
to give CeIII and a radical cation of the substrate. The radical cation can undergo mesolytic
cleavage to produce a radical and a cation. The resulting oxocarbenium ion is then trapped
by the pendant enol acetate nucleophile to yield the desired 4-tetrahydropyrone, while the
benzylic radical fragment undergoes further oxidation by CeIV and subsequent consumption
of the benzylic cation by nitrate anion to produce the observed benzylnitrate by-product.
Figure 17: Proposed ETIC reaction pathway
2.2 INITIAL STUDIES: AN APICULAREN MODEL
Initially, the most pressing research issue to be addressed was whether or not our key ETIC
reaction would be feasible for a synthesis of apicularen. This section describes our design
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and synthesis of a model system of the apicularen A core. The model cyclization substrates
were subjected to ETIC conditions, and our observations and conclusions are included.
2.2.1 Design and Synthesis of a Model System
To investigate whether the envisioned ETIC reaction would occur, we designed a truncated
model of apicularen A that we could synthesize rapidly and observe for reactivity. In or-
der to investigate any possible conformational effects (that is, whether or not any of the
diastereomers show any bias over the others for fragmentation and/or cyclization due to
stereochemical configuration), all four diastereomers of the apicularen core were considered
and synthesized (Figure 18). Notable features of this model system are:
1. a ten-membered lactone to approximate the apicularen core
2. the dimethyl-p-methoxybenzyl electroauxiliary
3. an enol acetate that will act as a latent enolate
4. the absence of the C3 oxygenation, which must later be included in precursors to the
natural product
5. an inert n-hexyl side chain, which must later be replaced with a functional handle in
precursors to the natural product
Figure 18: Model cyclization substrates
A significant challenge lies in the formation of doubly-secondary ethers. In the context of
our pursuit of apicularen, an attractive tactic to achieve their synthesis is the addition of a
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three-carbon nucleophile to an acetal (Figure 19). The convergent nature of synthesizing an
acetal linkage allows for molecular complexity to be established in a rapid and facile manner.
Figure 19: Acetal propargylation tactic to access doubly-secondary ethers
To secure the four diastereomers of our model system, both anti-diol 79 and syn-diol 80,
and aldehyde 85 were required. The syntheses (Figure 20) of the requisite diols commenced
with the treatment of commercially available 1-(4-methoxy-phenyl)-propan-2-one (76) with
base and iodomethane to produce bis-methylated product 77 in 82% yield. After treatment of
77 with LDA and heptanal, β-hydroxyketone 78 was available in 81% yield for either syn- or
anti- reduction to diols 79 and 80. If both isomeric diols are simultaneously desired, NaBH4
serves as a suitable reducing agent, as 79 and 80 are separable via flash chromatography. The
stereochemical configurations of diols 79 and 80 were determined by 13C NMR analysis39 of
the derivative acetonides 81 and 82. The synthesis of aldehyde 85 was accomplished in a
two-step procedure. Commercially available ethyl-2-bromobenzoate 83 and allyltributyltin
were coupled under Stille conditions40 to yield 84 in 85% yield, and subsequent ozonolysis
produced aldehyde 85 (65%).
With the configuration of the diols confirmed and aldehyde 85 in hand, acetal 87 (Fig-
ure 21) was assembled via the Noyori protocol in 90% yield.38 The diastereomeric cycliza-
tion substrates 94 and 95 have the (13,15-anti-) configuration, and were available through
propargylation of anti-acetal 87 to give 88 and 89 as a 55:45 mixture of diastereomers (70%
chemical yield). Ester hydrolysis yielded seco-acids 90 and 91 (91% yield), and lactonization
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according to the Yamaguchi41 protocol yielded lactones 92 and 93 in 68% yield, which were
separable via flash chromatography. Stereochemical assignments were made by analyzing
NOESY correlations of lactones 92 and 93. Ruthenium-catalyzed enol acetate formation42
provided 94 (57%)and 95 (51%).
The (9,13-syn-, 13,15-syn-) diastereomer 101 was available through the syn-acetal 97
(Figure 22). The acetal-opening of the syn-acetal proceeded to 98 with excellent stereose-
lectivity; only one isomer, assigned by analogy to literature precedent43 (see also Figure 19)
as the (9,13-syn-) stereoisomer was observed in 70% yield. Hydrolysis of the ester led to
seco-acid 99 (98%), and Yamaguchi lactonization41 formed lactone 100 (35%). Enol acetate
formation conditions42 secured cyclization substrate 101 in 35% yield.
The synthesis of cyclization substrate 106 required special attention. The necessary
(13,15-syn, 9,13-anti) relative stereochemical configuration was not available through propar-
gylation44 of 97, as the only isomer of the product observed had the (9,13-syn, 13,15-syn)
relationship. Thus, the synthesis of 106 (Figure 23) had to proceed through the anti- acetal
87, and a Mitsunobu inversion was implemented later to establish the correct configuration
at C15, confirmed by analysis NOESY correlations of lactone 105.
2.2.2 Conclusions from Preliminary ETIC Studies
When the test cyclization substrates were subjected to ETIC conditions, none of them led to
any of the desired product. We observed no fragmentation of the benzylic C–C bonds, and
the major isolate when the reactions were conducted at room temperature was unreacted
starting material. When the reactions were heated 100 ◦C or greater, the only changes in
the 1H NMR spectra from the starting materials to the isolated products were substitution
of the PMB arene, suggesting nitration via a nucleophilic aromatic substitution reaction
with nitrate anion as the nucleophile. The only other products observed when the reactions
were heated to the point of thermal decomposition were spectrally unrecognizable aliphatic
degradation products. These obervations led us to conclude that an oxocarbenium ion
may not readily form in the ten-membered lactone of the apicularen core. In order for
oxocarbenium ion formation to proceed, two sp3 atoms in the ring must re-hybridize to sp2.
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It is likely that re-hybridization introduces too much strain to the lactone ring to make
ionization feasible.
The sterically demanding dimethyl-p-methoxy benzyl substituent on the ten-membered
ring is thought to be cumbersome with respect to the conformations the substrate can access,
further restricting access to configurations that would allow for fragmentation. In order for
a fragmentation event to occur, the lone pair of the oxygen atom must overlap with the σ*
orbital of the benzylic C–C bond45 (Figure 24). The conformationally restrictive bulk of
the quaternary center at the benzylic position likely prohibits certain conformations from
being readily accessible. If this sterically large substituent could be replaced with a smaller
electroauxiliary, benzylic C–C bond cleavage might be possible to form an oxocarbenium ion
in the apicularen core. Tu and Floreancig have since shown that, under certain oxidative
conditions, an oxocarbenium ion can indeed be formed in within a macrocycle.46
Wemade an acyclic version of our apicularen model where the lactone had not been estab-
lished in order to eliminate the ring strain that we hypothesized was preventing oxocarbenium
ion formation. The synthesis of an acyclic ETIC substrate (Figure 25) involved acylation of
98 to yield 107, and subsequent enol acetate formation to yield acyclic cyclization substrate
108. When subjected to ETIC conditions, 108 underwent smooth cyclization to 109 in 51%
yield. A single diastereomer was observed, assigned as the syn-tetrehydropyran by NOESY.
Attempted ester hydrolysis was unproductive, causing decomposition of the starting mate-
rial, illustrating the base-lability of these 4-tetrahydropyrones. With this successful ETIC
reaction we could move ahead in our studies, confident in our ability to complete the syn-
thesis. Ring strain concerns likely preclude ETIC directly onto a macrolactone from being
viable, but an ETIC reaction will be possible if the lactone has not yet been established in
the cyclization substrate.
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Figure 20: Synthesis of diols 79 and 80 and aldehyde 85
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Figure 21: Synthesis of cyclization test substrates 94 and 95
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Figure 22: Synthesis of cyclization test substrate 101
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Figure 23: Synthesis of cyclization test substrate 106
Figure 24: Preferred conformation for radical cation carbon-carbon bond cleavage
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Figure 25: A successful ETIC reaction performed prior to establishing the macrolactone
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3.0 CONSTRUCTION OF THE C1-C15 FRAGMENT OF APICULAREN A
3.1 CHALLENGES PRESENTED BY INCORPORATING C3
OXYGENATION
Moving toward a synthesis of apicularen A required the modification of our model system
from Chapter 2. Useful intermediates for the purpose of a total synthesis require an oxygen
atom at the C3 position. Furthermore, the n-hexyl side chain from the model system would
have to be elaborated to include a functional handle that would allow us to append the
apicularen side chain (or intersect a known synthetic route to arrive at a formal synthesis).
Our initial efforts to modify our model system toward apicularen A are shown in Figures 26
and 27. In keeping with our acetal propargylation strategy, we prepared requisite aldehyde
117. We envisioned introduction of the apicularen side-chain using a vinyl iodide as a
functional handle,31;33 or possibly a functionally equivalent acrylic acid.27;30 Aldehyde 117
was synthesized (Figure 26) beginning with conversion of (E)-methyl but-2-enoate (111) to
the corresponding silyl ketene acetal47 112 in 56% yield. Dimethyl-1,3-acetonedicarboxylate
(113) was converted to the 1,3-allenedicarboxylate48 (114) in 92% yield. Heating 112 and
114 in refluxing benzene37 produced arenes 115/116 as a mixture of the phenol and methyl
ether analogs. Further treatment with base and iodomethane secured 116 (19% over two
steps). The low yield was due to incomplete aromatization; by-products were observed
wherein annulation had occured, but a lack of aromatic proton peaks in the 1 NMR spectra
of these side-products indicates that the acetal had not collapsed. Subsequent reduction of
the desired arylmethyl carboxylate allowed for isolation of aldehyde 117.
The syn diol 127 was prepared as shown in Figure 27. Synthesis of diol fragment 127
proceeded starting from fluoroanisole 118 and isobutyronitrile (119) to yield49 homobenzylic
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Figure 26: Preparation of aldehyde 117
nitrile 120 (94%). Reduction and hydrolysis yielded aldehyde 121 (97%), and Grignard
addition/acylation provided homoallylic acetate 123 (90%). Treatment of 123 with NBS
afforded bromohydrin 124 in 63% yield as a 3:1 mixture of diastereomers (syn- to anti-
confirmed by subsequent epoxidation).
A hydrolytic kinetic resolution was performed on scalemic 134 and 125 (prepared by
a Leighton asymmetric allylation50 into aldehyde 121) to confirm the syn- configuration
of the compound. As seen in (Figure 28), homoallylic alcohol 122 was epoxidized using
achiral mCPBA, and the result was a mixture of epoxides with a dr of 1.5:1, as determined
by NMR. After protection of the alcohol as the acetate, the 1.5:1 mixture of diastereomers
was subjected to the (R, R) enantiomer of Jacobsen’s salen-cobalt catalyst51. The (R, R)
enantiomer of the catalyst is known to hydrolyze epoxides with the same geometry of the
(S)-epoxide 134. The observation that the dr had increased to 3:1 (the peaks corresponding
the the major isomer were enhanced in the NMR spectrum) means that the diastereomeric
mixture was enriched with the R-epoxide 125 by removing the S-epoxide 134 by selective
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Figure 27: Synthesis of vinyliodide 130
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hydrolysis, confirming the identity of the major diastereomer as 125.
Figure 28: Hydrolytic kinetic resolution as confirmation of stereochemical configuration
Treatment of 124 with an alkoxide base provided epoxy-acetate 125 (49%). Opening
the epoxide 125 (Figure 27) with trimethylsilyl acetylene52 yielded 126 in 97% yield, and
basic methanolysis provided diol 127 (74%). With aldehyde 117 and use of the Noyori
protocol,38 acetal 129 was accessed in 79% yield. Hydrozirconation and quenching with
iodine53 resulted in vinyl iodide 130 (71%). When subjected to typical Lewis acidic condi-
tions43;44;54;55;56;57;58;59 in the presence of allenyltributylstannane, 130 failed to undergo the
desired addition reaction to the acetal center, the major isolate being unreacted starting ma-
terial. Since the significant differences between substrate 130 and 98 are 1) the introduction
of the C3 substituent and 2) the modification of the n-hexyl sidechain of 98 to the vinyl
iodide sidechain of 130, and since 98 underwent propargylation while 130 did not, one of
these two modifications must be causing the lack of reactivity in the case of 130.
To investigate whether the substitution at C3 was at fault, we prepared 135, lacking an
oxygen atom at C3. When subjected it to acetal-opening conditions (Figure 29), this analog
underwent smooth propargylation to the desired product 136. This result demostrated that
the vinyl iodide was not causing propargylation difficulties in the case of 130, but rather the
presence of the C3 substituent was problematic. The presence of the C3 substituent likely
causes a conformational change in the benzonic ester, rotating it out of conjugation with
the aromatic ring. Either this conformational change itself is impeding the propargylation
reaction, or the change in electronics due to a change in the pi-orbital network is somehow
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inhibiting formation of a proximal oxocarbenium ion. If we were to continue with our
apicularen synthesis, we needed to solve this problem in order to move synthetic material
through the reaction sequence.
Figure 29: Evidence that substituent at C3 inhibits propargylation
In the course of our studies to investigate the acetal ionization/nucleophilic addition
behavior, we arrived at acetal substrate 142. Lacking a side-chain branch, this acetal is de-
rived from a primary/secondary diol. Our hypothesis was that the lack of a sidechain branch
would reduce steric crowding around the reactive acetal center and allow for greater access to
the electrophilic site by the allene nucleophile under the reaction conditions. The fact that
acetal 142 underwent the desired reaction to yield propargyl derivative 143 represented one
of our initial successes in terms of reestablishing the desired propargylation reactivity. If we
had been unable to access a doubly-secondary ether moiety, our synthesis would have had
to have been abandoned. With 143 in hand, we were able to press forward and investigate
downstream reactions and events in the synthetic sequence.
The synthesis of 143 is shown in Figure 30. We adopted Kozikowski’s protocol60 for a
de novo synthesis of the salicylate arene; this protocol proved more reliable, reproducible,
stable to ambient moisture, and higher yielding than the arene synthesis in Figure 26. Us-
ing allene 1,3-dicarboxylate 11448 as in our previous work, the diene was changed to 3-
hydroxy-2-pyrone (138), which is available61 from the potassium bisulfate-mediated double-
dehydration-decarboxylation-lactonization of readily available mucic acid (137), though the
low yield in this process is due to formation of carboxyfuran side-products. When 138 and
allene 114 are heated in toluene for 72 hours, the two undergo a formal [4+2] cycloaddition
followed by extrusion of CO2 and isomerization to yield salicylate 115 in 78% yield. Protec-
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tion of the phenol as the p-toluenesulfonate furnishes 139 in an 87% yield. The tosyl group
was chosen to protect the phenol because of its stability62 to harsh reaction conditions (LAH
and pTSA for instance), and the ease of its removal with Mg0 in methanol.63 After reduction
with one equivalent of DIBAL, aldehyde 140 was isolated (97%).
Figure 30: Synthesis and propargylation of acetal 142
Diol 141 was chosen as a coupling partner for aldehyde 140 because it lacks an alkyl
substituent at C15, which allows the Lewis acid greater physical access to the dioxane of
the resulting acetal during the subsequent propargylation step. Diol 141 was available from
intermediate 122 via ozonolysis and reductive breakdown of the ozonide with NaBH4 (35%).
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The formation of an acetal 142 via condensation of diol 141 with aldehyde 140 proceeded
in a 52% yield.
When acetal 142 was subjected to acetal-opening conditions (Figure 30), three com-
pounds were isolated: starting material, the Friedel-Crafts product 144 and the desired
product 143. Recovered starting material can be resubjected to the reaction conditions, and
successive yields of 143 can be isolated in an iterative fashion. In our most successful ex-
periment, we subjected 3.5 grams of the acetal 142 to the reaction conditions and were able
to isolate 450 mg (12% isolated yield) of the desired propargylated product 143 as a single
diastereomer. The resulting primary alcohol 143 was oxidized (Figure 31) using the Dess-
Martin periodinane64 to yield the corresponding aldehyde 145 in quantitative yield. This
aldehyde presents an opportunity to establish the absolute stereochemical configuration at
C15. A zinc-mediated allylation of aldehyde 145 did not provide any diastereoselectivity,
and led to secondary alcohols 146 and 147 as a mixture of diastereomers. Subsequent enol
acetate formation to 148 + 149 and TBS protection provided 150, an ETIC substrate.
Treatment of 150 with CAN formed cyclized product 151 in a 38% yield, demonstrating
the feasibility of an ETIC reaction towards apicularen in the presence of the C3-oxygenated
benzoic acid moiety.
In this section I have shown that we were able to overcome difficulties with the acetal
propargylation technology as applied to our apicularen system. With a proof-of-concept
experiment (142 -> 143), we were able to carry on with our synthesis to later-stage inter-
mediates.
3.2 IMPROVED SYNTHESIS OF DOUBLY-SECONDARY ETHERS
Though the desired propargylation process had been reestablished in the case of acetal
142, further experimentation with acetal-opening conditions was required to improve yields
to acceptable levels for practical synthetic study of later-stage synthetic steps. The best
results (Figure 32) were obtained using acetal 154, containing an unprotected phenol, with
allenyltrimethylsilane and a pre-cooled Ti-Lewis acid. The preparation of acetal 154, and the
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Figure 31: Probing for ETIC feasibility
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subsequent application of an ETIC reaction to construct the C1–C15 fragment of apicularen
A are shown in Figure 32.
While the yield of the desired doubly-secondary ether was increased to a modest 50%,
the diastereomers were obtained in a ratio 6.8:1. Though the diastereomers proved insepa-
rable, this route allowed us to synthesize enough material to investigate the ETIC reaction,
and make improvements to those yields as well. This cyclization demonstrates that an ETIC
reaction may be performed on a substrate possessing two potentially fragmenting (homoben-
zylic ether) C−C bonds. Exclusive selectivity was observed for the desired fragmentation to
occur, due to differentiated rates of processes that follow the initial single-electron oxidation;
the electron rich PMB electroauxiliary possesses substitutions at the benzylic position that
weaken the carbon–carbon bond relative to the benzylic carbon–carbon bond of the salicy-
late. Extra equivalents of CAN and higher reaction temperatures were required for the first
time in our group’s studies of the ETIC reaction, suggesting a certain amount of reversibility
in the initial oxidation step. The route shown in Figure 32 provides high enough yields in
the propargylation and ETIC steps to be of practical use in continuing with the synthesis.
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Figure 32: Synthesis of the C1–C15 fragment of apicularen
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4.0 PROGRESS TOWARD COMPLETION OF AN APICULAREN
SYNTHESIS
4.1 PROGRESS IN ACETAL PROPARGYLATION REACTIONS
One remaining challenge is the macrolactonization step. The protecting group scheme in
substrate 158 proved undesirable due to difficulties in hydrolyzing the methyl ester to obtain
the derivative carboxylic acid in good yields. The fact that the benzyl ester is doubly-ortho
substituted likely leads the carbonyl to prefer a conformation orthogonal to the plane of the
arene, thereby blocking access to the pi* orbital and inhibiting nucleophilic attack from a
pendant alcohol nucleophile. Furthermore, the elaboration of the sidechain from a secondary
alcohol to a primary alcohol adds undesirable synthetic steps to the route; more desirable
would be to utilize an acetal derived from a doubly-secondary 1,3-diol.
In order to address concerns with the salicylate protecting group scheme, we employed
the cyclic acetonide motif (see Figure 33) used by both De Brabander28 and Nicolaou31 in
their apicularen syntheses. The cyclic acetal forces the ester carbonyl to align with the arene
in a coplanar fashion, allowing for greater accessibility for incoming nucleophilic attack and
therefore greater ease in eventual lactonization.
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Figure 33: Synthesis of De Brabander’s aldehyde 163
As part of the further evolution of our route to apicularen, we developed conditions for
the propargylation of a more complex acetal, the assembly of which is shown in Figures 34
and 35. Alkene 123 was converted to bromohydrins 164 and 124 (99% yield, dr = 3:1,
diastereomers separable via flash column). The bromohydrins were converted to epoxides
132 and 133, which were in turn elaborated to allylic alcohols 165 and 166. 13C NMR
analysis of the derivative acetonides 167 and 168 confirmed the relative stereoconfiguration
of both diols.
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Syn diol 166 was coupled with aldehyde 163 to provide doubly-branched acetal 170. The
propargylation of 170 to 171 proceeded in a 50% yield, with a dr of 1.01:1. The advantage of
this route, however, is the fact that the derivative TBS ethers 173 and 174 were readily sep-
arable by typical flash column chromatography. This is significant because separable isomers
are available for the first time in our studies toward apicularen, greatly simplifying analysis,
characterization and spectral interpretation of intermediates. Additionally, the synthesis of
171 and 172 establishes a doubly-secondary ether with a functional handle required for in-
stallation of the apicularen sidechain prior to the point of synthetic convergence, obviating
the need to install the sidechain branch subsequent the acetal assembly point of convergence.
In this section, I have shown that we were able to move material through the synthetic
sequence in good enough yields to investigate the ETIC reaction thoroughly in the context
of our apicularen synthesis. Furthermore, we could move ahead to later-stage intermediates
with ample material available as samples of single diastereomers.
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Figure 34: Synthesis of allyl diols 165 and 166
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Figure 35: Route to separable doubly-secondary ether diastereomers (asterisks denote unas-
signed stereocenters)
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4.2 LACTONIZATION STUDIES
The TBS ethers 173 and 174 were separated via flash chromatography and advanced through
the synthetic scheme independently. The alkynes were converted to the enol acetates 175
and 177, respectively (Figure 36). Both diastereomers of the enol acetate underwent ETIC
processes to produce 177 and 178, and the silyl groups were removed to yield free alcohols
179 and 180. Despite the fact that we’re dealing with two diastereomers due to the virtually
nonexistent diastereoselectivity of the propargylation of acetal 170, it is desirable to carry
both diastereomers towards the macrolactone stage, based on the hypothesis that the relative
stereochemical configuration of 179 and 180 will eventually be established by straightforward
NOESY analysis of the derivative 10-membered lactones. According to Rizzacasa’s studies,34
the desired lactones 183 and 184 are convertible to the thermodynamically more stable
(9,13-anti 13,15-syn) configuration of the natural product.
The macrolactonization step remains an active research problem. Treatment of lactoniza-
tion substrates 179 and 180 with NaH in THF (in analogy to De Brabander and Nicolaou’s
strategies) did not yield the desired macrolactones 183 and 184, but rather two undesired
side-product lactones, the spectral data of which are consistent with structural assignments
corresponding to 181 and 182. This proposed structure is consistent with NMR data gath-
ered, and the six-membered lactones are likely formed through opportunistic oxygen present
in the basic reaction media. A proposed possible mechanism for the formation of this un-
desired product is shown in Figure 37. Alkoxide formation could lead to deprotonation of
the proximal α-hydrogen, producing an enolate that could attack ambient atmospheric oxy-
gen. In the basic reaction medium, the resulting α-peroxy ketone could be deprotonated to
effect elimination of water. Liberated hydroxide is possibly the nucleophile that cleaves the
dimethyl acetal and produces the carboxylate. At this stage, a possible intramolecular SN2
process is invoked, due to the fact that stereochemical integrity of the starting materials
was preserved in the products. That is, since 179 and 180 were subjected to the reaction
conditions independently, and since the observed products were also distinguishably differ-
ent diastereomers by NMR, a stereospecific rather than stereoselective lactonization event is
postulated. The alternative rupture of the cyclic ether by elimination following deprontona-
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tion of an α-hydrogen seems less likely, as this type of process would lead to diastereomeric
scrambling. The depicted 6-exo cyclization was chosen rather than the presumably compet-
itive 5-exo cyclization based on the fact that under these conditions, the reaction should be
reversible, and the six membered ring is presumed to be thermodynamically preferred to the
more strained 5-membered ring product.
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4.3 VISION FOR COMPLETION OF THE SYNTHESIS
4.3.1 Macrolactonization
My hypothesis is that the lactonization of 179 and 180 will proceed in the absence of oxygen.
The lactonization experiments should be repeated under rigorously deoxygenated conditions.
A secondary possibility is to either reduce or otherwise suitably protect the ketones 179
and 180 and proceed with the macrolactonizations at the tetrahydropyran oxidation state.
The tetrahydropyrans could be re-oxidized subsequent to lactonization in an effort to apply
Rizzacasa’s acid catalyzed epimerization at the ketone oxidation state.
4.3.2 Proposed Epimerization Under Acidic Conditions
Macrolactones 75 and 185 with the tetrahydropyrone oxidation state are desirable targets, as
they are the closest analogies to Rizzacasa’s epimerization34 which is postulated to arrive at
the thermodynamically most stable configuration based on the reversibility of Michael/retro-
Michael additions under the reaction conditions (Figure 38). Alcohols 179 and 180 could
be independently carried forward to macrolactone 183, 184 (Figure 39) under rigorously
deoxygenated conditions, and the phenol could be protected as the methyl ethers (75 and
185). Based on Rizzacasa’s acid-promoted epimerization, I hypothesize that intermediates
75 and 185 will undergo the same thermodynamically controlled equilibration to arrive at
54, completing a formal synthesis of apicularen A.
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Figure 36: Undesired products from lactonization (asterisk indicates unassigned stereocenter)
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Figure 37: Proposed mechanism for formation of 181 and 182
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Figure 38: Proposed epimerizations based on Rizzacasa’s observation
4.3.3 Proposed Epimerization Under Basic Conditions
Tetrahydropyrans 186 and 188may be epimerizable under basic conditions (Figure 40) based
on observations by O’Doherty.36 My hypothesis is that intermediates 177 and 178 could be
carried on independently through the synthetic sequence shown in Figure 41. Tetrahydropy-
rones 177 and 178 could be reduced to the corresponding hydroxy-tetrahydropyrans 189
and 190 by way of axial hydride delivery using L-selectride. The secondary alcohols could
be protected as benzyl ethers (the benzyl group chosen to intersect Panek’s route), and the
TBS group removed to access 193 and 194. Macrolactonization promoted by sodium hydride
should proceed smoothly to yield 195 and 196, as there are no longer acidic α-hydrogens
present in the lactonization substrates as there were in Figure 36. The free phenol could be
converted to the MOM ether (also chosen to accomodate intersection with Panek’s route) to
produce 197 and 198, substrates to test the hypothesis that an O’Doherty-type epimeriza-
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Figure 39: Proposed completion of a formal synthesis (epimerization under acidic conditions)
tion will lead to 49, and complete a formal synthesis of apicularen A.
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Figure 40: Proposed epimerizations based on O’Doherty’s observation
4.3.4 Conclusion
An ETIC reaction has been successfully applied to access late-stage intermediates in the
context of an effort towards apicularen A. Epimers 179 and 180 represent the most advanced
intermediates synthesized. There remain two synthetic challenges to address before a formal
synthesis can be acheived: 1) effecting macrolactonization, and 2) conducting a successful
epimerization of either 75 and 185 to 54 under acidic conditions, or of 197 and 198 to 49
under basic conditions.
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Figure 41: Proposed completion of a formal synthesis (epimerization under basic conditions)
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APPENDIX A
EXPERIMENTAL PROCEDURES SUPPLEMENT TO CHAPTER 2
Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were recorded
on Bruker Avance 300 spectrometers (300 MHz and 75 MHz, respectively), and Bruker
Avance 500 spectrometers (500 MHz and 125 MHz, respectively). The chemical shifts are
given in parts per million (ppm) on the delta (δ) scale. The solvent peak was used as
reference value. For 1H NMR: CDCl3 = 7.27 ppm. For
13C NMR: CDCl3 = 77.36 ppm. For
proton data: app = apparent; br = broad; s = singlet; d = doublet; t = triplet; q = quartet;
p = pentet; dd = doublet of doublets; dt = doublet of triplets; ddd = doublet of doublet
of doublets; dddd = doublet of doublet of doublet of doublets; ddt = doublet of doublet
of triplets; ddq = doublet of doublet of quartets; qd = quartet of doublets; m = multiplet.
High resolution and low resolution mass spectra were recorded on a VG 7070 spectrometer.
Infrared (IR) spectra were collected on a Mattson Cygnus 100 spectrometer. Samples for IR
were prepared as a thin film on NaCl plates. Analytical thin layer chromatography (TLC)
was performed on E. Merck pre-coated (25 nm) silica gel 60F-254 plates. Visualization
was done under UV (254 nm). Flash column chromatography was performed using ICN
SiliTech 32-63 60 A˚ silica gel. Reagent grade ethyl acetate, hexanes (commercial mixture),
ether, dichloromethane, benzene, acetone, and toluene were purchased from EM Science
and used as is for chromatography. Reagent grade methylene chloride (CH2Cl2) and 1,2-
dichloroethane (DCE) were distilled from CaH2 under N2. Diethyl ether (Et2O) was dried
by passage through an aluminum drying column. THF was dried by passage through an
aluminum drying column, except where noted. In these cases THF, was distilled from sodium
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benzophenone under N2. Anhydrous methanol (MeOH) was purchased from Aldrich and used
as is. All reactions were conducted under argon or nitrogen atmosphere, in oven or flame
dried glassware with magnetic stirring except were noted.
3-(4-Methoxyphenyl)-3-methylbutan-2-one (77)
(Previously reported compound65) To 1-(4-Methoxyphenyl)propan-2-one
(76) (Aldrich chemical company, 10.0 g, 60.8 mmol) in THF (100 mL) at
−78 ◦C was added iodomethane (19.0 g, 8.35 mL, 133.8 mmol). Potas-
sium tert-butoxide (15.0 g, 133.8 mmol) was added portion-wise and the temperature was
maintained at −78 ◦C for 30 min. The reaction warmed to room temperature and stirred
for 14 hours. The reaction was quenched at 0 ◦C with saturated ammonium chloride (100
mL), extracted with EtOAc (3x 50 mL), washed with brine (100 mL), dried over Na2SO4,
filtered and concentrated under reduced pressure to yield a crude orange oil. The oil was
distilled (2 torr, 98 ◦C) to yield the title compound as a light yellow oil (10.17 g, 87%): 1H
NMR (300 MHz, CDCl3) δ 7.17 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H),
1.91 (s, 3H), 1.46 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 211.6, 158.8, 136.4, 127.3, 114.4,
76.9, 55.5, 52.0, 25.5; IR (neat) 2973, 1707, 1513, 1253, 1184, 1126, 1034, 834 cm−1;
5-Hydroxy-2-(4-methoxyphenyl)-2-methylundecan-
3-one (78).
To a solution of diisopropyl amine (6.04 g, 8.36 mL, 59.7 mmol) in
60 mL THF at 0 ◦C was added n-butyl lithium (1.6 M in hexanes,
34.19 mL, 54.7 mmol) dropwise. The solution stirred for 10 minutes then was cooled to −78
◦C. To the solution of LDA at −78 ◦C was added ketone 77 (9.56 g, 49.7 mmol) in 40 mL
THF as a slow drip. The reaction stirred at −78 ◦C for 45 minutes, then was quenched at
0 ◦C with saturated ammonium chloride (40 mL), extracted with EtOAc (3 x 40 mL). The
combined organics were washed with 1 M HCl (100 mL), then brine (100 mL), dried over
MgSO4, filtered and concentrated under reduced pressure to yield the title compound as an
orange oil (14.89 g, 81%): 1H NMR (300 MHz, CDCl3) δ 7.17 (d, J = 8.8 Hz, 2H), 6.88
(d, J = 8.8 Hz, 2H), 3.85 (m, 1H), 3.80 (s, 3H), 3.06 (br s, 1H), 2.42 (dd, J = 17.4, 2.7
Hz, 1H), 2.27 (dd, J = 17.4, 8.7 Hz, 1H), 1.48 (s, 3H), 1.46 (s, 3H), 1.21 (br m, 10H), 0.85
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(dd, J = 6.9, 6.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 215.4, 158.9, 135.8, 127.5, 114.5,
76.9, 68.6, 55.5, 52.0, 44.0, 36.7, 32.1, 29.5, 25.7, 25.6, 22.9, 14.4; IR (neat) 3500, 2930, 2857,
1704, 1513, 1464, 1301, 1253, 1184, 1035, 833 cm−1; HRMS (EI): calcd for C19H30O3 (M+)
306.2195, found 306.2244.
(3S*,5R*)-2-(4-Methoxyphenyl)-2-methylundecane-
3,5-diol (79).
To a solution of β-hydroxyketone 78 (12.0 g, 39.16 mmol) in CH3CN
(65 mL) at −40 ◦C was added a solution of sodium triacetoxyboro-
hydride (41.5 g, 195.82 mmol in 130 mL 1:1 CH3CN:acetic acid) as a slow drip. The reaction
stirred at −40 ◦C for 48 hours then warmed to 0 ◦C in a large ice bath. The ice was then
allowed to melt as the reaction warmed to room temperature and stirred for an additional
24 hours. The reaction was quenched with 100 mL H2O, then carefully with solid NaHCO3.
The contents were extracted with EtOAc (3x 100 mL), and the combined organics were
washed with saturated NaHCO3 (100 mL). The organic solvent was removed under reduced
pressure and the oil that remained was suspended in ether (100 mL) and stirred with a 1:1
solution of 30% H2O2 : pH = 7 buffer (100 mL) for 2 hours at which time the aqueous layer
had turned cloudy. The contents were extracted with EtOAc (3x 50 mL), and the combined
organics were washed with brine (100 mL), dried over MgSO4, filtered and concentrated un-
der reduced pressure. The resulting oil was purified via flash column chromatography (SiO2,
20% EtOAc in hexanes eluent) to yield a sample that consisted of both “syn” and “anti”
stereoisomers of the desired product (5.85 g) and a second sample that was the desired “anti”
isomer (3.99 g, 33%): 1H NMR (300 MHz, CDCl3) δ 7.31 (d, J = 8.8 Hz, 2H), 6.88 (d, J =
8.8 Hz, 2H), 3.96 (dd, J = 3.3, 3.2 Hz, 1H), 3.81 (s, 3H), 2.7 (br s, 1H), 2.07 (d, J = 11.7
Hz, 1H), 1.47 (m, 6H), 1.36 (m, 13H), 0.88 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 158.0,
139.3, 127.9, 113.8, 76.1, 69.9, 55.5, 41.9, 37.5, 32.1, 29.6, 26.2, 24.2, 22.9, 14.4;
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(3S*,5S*)-2-(4-Methoxyphenyl)-2-methylundecane-
3,5-diol (80).
To a solution of β-hydroxyketone 78 (6.19 g, 20.2 mmol) in 100 mL
THF at −78 ◦C was added diethylmethoxyborane (2.63 g, 26.26
mmol) dropwise, followed by MeOH (1 mL). The mixture stirred for 45 minutes at −78 ◦C,
then sodium borohydride (2.29 g, 60.6 mmol) was added slowly. The reaction stirred for 2
hours at −78 ◦C, then was quenched with a 1:1:1 solution of MeOH : 30% H2O2 : 10% NaOH
(90 mL) and was stirred vigorously at room temperature for 1 hour. The contents were ex-
tracted with EtOAc (3x 50 mL), and the combined organics were washed with brine (100
mL), dried over MgSO4, filtered and concentrated under reduced pressure. The resulting
oil was purified via flash column chromatograhpy (20% EtOAc in hexanes eluent) to yield
a sample of both stereoisomers (2.30 g) and a sample of the desired “syn” isomer (1.81 g,
29%): 1H NMR (300 MHz, CDCl3) δ 7.30 (d, J = 8.0 Hz, 2H), 6.86 (d, J = 8.0 Hz, 2H),
4.00 (m, 1H), 3.88 (m, 1H), 3.80 (s, 3H), 1.48 (m, 2H), 1.38 (s, 3H), 1.34 (s, 3H), 1.28 (br
m, 10H), 0.884 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 158.0, 138.4, 127.9, 113.5, 80.2, 72.9,
55.4, 41.3, 37.6, 33.8, 32.0, 29.4, 25.3, 22.9, 22.5, 14.3;
(4R*,6S*)-4-Hexyl-6-(2-(4-methoxyphenyl)propan-2-
yl)-2,2-dimethyl-1,3-dioxane (81).
To a stirring solution of diol 79 (50 mg, 130 µmol in 2,2-
dimethoxypropane (2 mL) was added a catalytic amount of tosic
acid. The reaction stirred at ambient temperature for 17 hours, then was quenched with tri-
ethylamine. Contents were poured into a separatory funnel containing water and extracted
thrice with EtOAc, and the combined organics were washed with brine, dried over Na2SO4,
filtered and concentrated. The resulting crude oil was purified via flash chromatography
(20% EtOAc in hexanes as eluent) to yield the title compound (34 mg, 75%): 1H NMR (300
MHz, CDCl3) δ 7.28 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.6 Hz, 2H), 3.81 (m, 4H), 3.52
(m, 1H), 1.29 (br m, 24H), 0.9 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 157.9, 139.3, 128.0,
113.4, 100.5, 74.0, 55.5, 40.5, 36.2, 34.6, 32.1, 29.5, 26.2, 25.7, 25.1, 24.5, 23.4, 22.9, 14.4, 5.3;
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(4S*,6S*)-4-Hexyl-6-(2-(4-methoxyphenyl)propan-2-
yl)-2,2-dimethyl-1,3-dioxane (82).
To the diol 80 (50 mg, 130 µmol) in 2,2-dimethoxypropane (2 mL)
was added a catalytic amount of tosic acid. The reaction stirred
for 11 hours at ambient temperature, then was quenched with triethylamine (500 µL) and
poured into a separatory funnel containing 20 mL water. The contents were extracted thrice
with EtOAc, and the combined organics were washed with brine, dried over Na2SO4, filtered
and concentrated. The resulting oil was purified via flash chromatography (20% EtOAc in
hexanes as eluent) to yield the title compound (30 mg, 66%): 1H NMR (300 MHz, CDCl3)
δ 7.27 (d, J = 8.7 Hz, 2H), 6.82 (d, J = 8.7 Hz, 2H), 3.65 (br m, 5H), 1.28 (br m, 19H),
1.03 (m, 2H), 0.84 (br m, 6H); 13C NMR (75 MHz, CDCl3) δ 157.9, 139.5, 128.2, 113.5, 98.7,
69.7, 63.4, 55.5, 40.8, 36.9, 33.2, 32.1, 31.9, 31.2, 30.6, 29.5, 26.2, 25.4, 23.0, 20.0;
Ethyl 2-Allylbenzoate (84).
To a slurry of lithium chloride (4.44 g, 104.4 mmol) and Pd(PPh3)4 (2.02 g,
1.76 mmol) in THF (190 mL) was added ethyl-2-bromobenzoate (83). The
mixture stirred for 25 minutes, and allyltributyltin (13.87 mL, 45.2 mmol) was
added. The reaction was heated to reflux for six hours and quenched with water (80 mL).
Contents were extracted thrice with EtOAc. The solvent was removed and replaced with
ether. The organics were washed with 10% aqueous KF, and the white precipitate was fil-
tered. The process of washing with 10% KF and filtering was repeated four times. The ether
was evaporated in vacuo, and the resulting crude yellow oil was purified via flash column
chromatography (10% EtOAc in hexanes eluent) to yield the title compound (5.43 g, 82%):
1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 7.6 Hz, 1H), 7.44 (td, J = 7.5, 7.5, 1.1 Hz, 1H),
7.27 (m, 2H), 6.03 (ddt, J = 16.9, 10.4, 6.4 Hz, 1H), 5.06 (d, J = 0.77 Hz, 1H), 5.02 (ddd, J
= 8.8, 1.6, 1.1 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 3.78 (d, J = 6.4 Hz, 2H), 1.40 (t, J = 7.1
Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 168.0, 141.7, 137.8, 132.2, 131.2, 130.8, 130.4, 126.4,
115.8, 61.1, 38.7, 14.6;
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Ethyl 2-(2-Oxoethyl)benzoate (85).
(Previously reported compound66) Alkene 84 (761 mg, 4 mmol) was dissolved
in CH2Cl2 (10 mL) and cooled to −78 ◦C. A steady stream of ozone was
bubbled through the solution for one hour. Triphenylphosphine (1.15 g, 4.4
mmol) was added and the reaction warmed to 0 ◦C and stirred for 45 minutes. Solvent was
evaporated in vacuo and the resulting crude oil was purified via flash chromatography (20%
EtOAc in hexanes eluent) to yield the title compound (534 mg, 70%): 1H NMR (300 MHz,
CDCl3) δ 9.80 (s, 1H), 8.08 (dd, J = 7.8 Hz, 1H), 7.52 (td, J = 7.5, 1.3 Hz, 1H), 7.40 (td, J
= 7.5, 1.1 Hz, 1H), 7.25 (d, J = 7.6 Hz, 1H), 4.35 (q, J = 7.1. Hz, 2H), 4.08 (s, 2H), 1.39
(t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 198.6, 166.5, 134.8, 132.3, 130.7, 129.5,
127.3, 60.7, 49.2, 13.9;
(4R*,6S*)-4-Hexyl-6-(2-(4-methoxyphenyl)propan-2-yl)-
2,2,8,8-tetramethyl-3,7-dioxa-2,8-disilanonane (86).
A solution of anti-diol 79 (380 mg, 1.23 mmol) in CH2Cl2 (4 mL)
was cooled to −78 ◦C. To this solution was added 2,6-lutidine (572
µL, 4.93 mmol), and the mixture stirred for ten minutes, then TMSOTf (2 EQ) was added
dropwise. The reaction stirred for 15 minutes, and was quenched with water (10 mL). Con-
tents were extracted thrice with CH2Cl2, and the combined organics were washed with 1 M
HCl, then brine, dried over Na2SO4, filtered and concentrated to yield the title compound
(547 mg, 98%): 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.1 Hz, 2H), 6.84 (d, J = 8.7
Hz, 2H), 3.90 (dd, J = 8.1, 1.6 Hz, 1H), 3.80 (s, 3H), 3.59 (m, 1H), 1.36 (m, 2H), 1.25 (br
m, 16H), 0.876 (dd, J = 6.9, 6.3 Hz, 3H), 0.079 (s, 9H), 0.049 (s, 9H); 13C NMR (75 MHz,
CDCl3) δ 157.8, 148.0, 140.5, 128.0, 113.4, 78.7, 71.4, 55.3, 42.4, 41.9, 38.8, 32.16, 29.78,
26.5, 25.8, 24.1, 22.9, 14.4, 1.48, 1.20;
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Ethyl 2-(((4R*,6S*)-4-hexyl-6-(2-(4-methoxyphenyl)prop-
an-2-yl)-1,3-dioxan-2-yl)methyl)benzoate (87).
To a solution of aldehyde 85 (2.51 g, 13.1 mmol) and bis-TMS ether
86 (5.92 g, 13.1 mmol) in CH2Cl2 (65 mL) at −78 ◦C was added
TMSOTf (253 µL, 1.31 mmol). The reaction stirred for two hours
at −78 ◦C, then was quenched with pyridine (160 µL, 1.96 mmol) and poured into satu-
rated NaHCO3. Contents were extracted thrice with CH2Cl2, and the combined organics
were washed with brine, filtered, dried over MgSO4, filtered and concentrated. The resulting
crude oil was purified via flash chromatography (10% EtOAc in hexanes eluent) to yield the
title compound (5.67 g, 90%): 1H NMR (300 MHz, CDCl3) δ 7.85 (dd, J = 7.7, 1.2 Hz, 1H),
7.42–7.30 (m, 3H), 7.23 (d, J = 8.9 Hz, 2H), 6.80 (d, J = 8.9 Hz, 2H), 4.97 (dd, J = 5.9, 4.3
Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 3.93 (m, 1H), 3.80 (s, 3H), 3.67 (dd, J = 11.7, 2.2 Hz,
1H), 3.32 (dd, J = 13.3, 4.3 Hz, 1H), 3.20 (dd, J = 13.3, 6.0 Hz, 1H), 1.85–1.79 (m, 1H),
1.70 (dt, J = 12.6, 6.2 Hz, 1H), 1.39 (t, J = 7.1 Hz, 3H), 1.34–1.05 (m, 15H), 0.953 (d, J =
13.2 Hz, 1H), 0.863 (dd, J = 7.1, 6.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 167.9, 157.7,
138.8, 138.2, 133.1, 131.3, 130.9, 130.2, 127.8, 126.3, 113.3, 95.2, 79.3, 72.3, 60.8, 55.1, 40.7,
40.1, 31.9, 30.5, 29.1, 28.6, 26.1, 25.7, 22.9, 22.6, 21.1, 14.4, 14.2;
Ethyl 2-(2-((3S*,5R*)-5-hydroxy-2-(4-methoxyphenyl)-
2-methylundecan-3-yloxy)pent-4-ynyl)
benzoate (88, 89).
Mixed Lewis acid was prepared by addition of TiCl4 (11.1 mL,
101.26 mmol) to a solution of Ti(Oi-Pr)4 (9.89 mL, 33.75 mmol)
in CH2Cl2 (840 mL). To the acetal 87 (5.43 g, 11.25 mmol) and
allenyltributyltin (10.0 mL, 33.75 mmol) in CH2Cl2 (280 mL) at −42 ◦C was added the mixed
Lewis acid solution in one slow, smooth pour. After ten minutes, reaction was quenched with
pyridine (45 mL) followed by methanol (45 mL). Contents were poured into 1 M HCl (450
mL), and extracted thrice with CH2Cl2. Combined organics were wahed with brine, dried
over MgSO4, filtered and concentrated. The resulting crude brown oil was purified via flash
chromatography (100% hexanes–40% EtOAc in hexanes gradient, 10% increments, as eluent)
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to yield the title compound as a 55:45 mixture of diastereomers, as determined by 1H NMR
analysis (4.13 g, 70%): 1H NMR (300 MHz, CDCl3) δ 7.93–7.86 (m, 1H), 7.46–7.32 (m, 3H),
7.16–7.14 (m, 2H), 6.83–6.75 (m, 2H), 4.42–4.42 (m, 2H), 3.98–3.95 (m, 1H), 3.78–3.77 (m,
5H), 3.5–3.3 (m, 1H), 3.16–3.0 (m, 1H), 2.6–2.4 (m, 1H), 2.3–2.2 (m, 1H), 2.07 (m, 1H),
1.7–1.0 (m, 18H), 0.95–0.7 (m, 5H);
2-(2-((3S*,5R*)-5-Hydroxy-2-(4-methoxyphenyl)-2-
methylundecan-3-yloxy)pent-4-ynyl)benzoic acid (90,
91).
To a solution of racemic epimers 88 and 89 (4.13g, 7.90 mmol)
in methanol (120 mL) and water (60 mL) was added lithium hy-
droxide monohydrate (18.89 g, 450 mmol). Reaction vessel was
heated to 60 ◦C for 15 hours. Contents were acidified to pH 1 with 1 M HCl and extracted
thrice with ether. The combined organics were washed with brine, dried over MgSO4, filtered
and concentrated to yield the title compound as a light yellow oil (3.56 g, 91%): 1H NMR
(300 MHz, CDCl3) δ 8.0–7.8 (m, 1H), 7.6–7.4 (m, 1H), 7.4–7.3 (m, 2H), 7.2–7.1 (m, 1H),
7.1–7.0 (m, 1H), 6.9–6.7 (m, 2H), 4.2–4.1 (m, 1H), 4.0–3.8 (m, 1H), 3.8–3.7 (m, 4H), 3.6–3.4
(m, 2H), 3.3–3.1 (m, 1H), 2.9–2.8 (m, 1H), 2.6–2.4 (m, 1H), 2.2-2.0 (m, 2H), 1.6–0.8 (m, 21H);
(3R*,5S*,7R*)-3-Hexyl-5-(2-(4-methoxyphenyl)propan-2-
yl)-7-(prop-2-ynyl)-4,5,7,8-tetrahydrobenzo[g][1,5]dioxecin-
1(3H)-one (92).
To a solution of the seco-acids 90 and 91 (1.22 g, 2.47 mmol) in THF
(30 mL) at 0 ◦C was added triehtylamine (2.07 mL, 14.82 mmol), fol-
lowed by 2,4,6-trichlorobenzoyl chloride (1.93 mL, 12.35 mmol). The
reaction stirred for 15 minutes at 0 ◦C and the contents were poured carefully, slowly and
smoothly into a solution of DMAP (3.02 g, 24.7 mmol) in toluene (1200 mL) at ambient
temperature, and stirred for 15 minutes. The reaction was stripped of solvent under reduced
pressure, and the resulting crude white semi-solid was purified via flash chromatography
(10% EtOAc in hexanes eluent) to yield 795 mg (68%) of the title compound (still as a
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1:1 mixture of racemic epimers). A second flash column eluted with toluene separated the
diastereomers, yielding 365 mg of the (9,13-syn-, 13,15-anti-) isomer 93 and 220 mg of the
(9,13-anti-, 13,15-anti-) isomer 92: 1H NMR (300 MHz, CDCl3) δ 7.92 (d, J = 7.6 Hz, 1H),
7.5–7.3 (m, 2H), 7.29–7.20 (m, 3H), 6.86 (d, J = 8.7 Hz, 2H), 5.23 (m, 1H), 4.2–4.1 (m,
2H), 3.79 (s, 3H), 3.66 (m, 1H), 2.5–2.2 (m, 3H), 2.0–1.8 (m, 2H), 2.7–2.55 (2 singlets, 2H),
1.5–1.3 (2 singlets, 7H), 1.3–1.2 (m, 3H), 1.2–1.0 (m 6H), 0.85 (t, J = 7.0 Hz, 3H), 0.77 (m,
1H);
(3R*,5S*,7S*)-3-Hexyl-5-(2-(4-methoxyphenyl)propan-2-yl)-
7-(prop-2-ynyl)-4,5,7,8-tetrahydrobenzo[g][1,5]dioxecin-
1(3H)-one (93).
To a solution of the seco-acids 90 and 91 (1.22 g, 2.47 mmol) in THF
(30 mL) at 0 ◦C was added triehtylamine (2.07 mL, 14.82 mmol), fol-
lowed by 2,4,6-trichlorobenzoyl chloride (1.93 mL, 12.35 mmol). The
reaction stirred for 15 minutes at 0 ◦C and the contents were poured carefully, slowly and
smoothly into a solution of DMAP (3.02 g, 24.7 mmol) in toluene (1200 mL) at ambient
temperature, and stirred for 15 minutes. The reaction was stripped of solvent under reduced
pressure, and the resulting crude white semi-solid was purified via flash chromatography
(10% EtOAc in hexanes eluent) to yield 795 mg (68%) of the title compound (still as a
1:1 mixture of racemic epimers). A second flash column eluted with toluene separated the
diastereomers, yielding 220 mg of the (9,13-anti-, 13,15-anti-) isomer 92 and 365 mg of the
(9,13-syn-, 13,15-anti-) isomer 93: 1H NMR (300 MHz, CDCl3) δ 7.85 (d, J = 7.5 Hz, 1H),
7.5–7.2 (m, 5H), 6.87 (d, J = 8.7 Hz, 2H), 4.91 (m, 1H), 4.25 (d, J = 14.2 Hz, 1H), 4.0–3.81
(m, 2H), 3.80 (s, 3H), 2.72 (dd, J = 14.2, 2.7 Hz, 1H), 2.3–2.1 (m, 2H), 2.0 (s, 1H), 1.8–1.6
(m, 2H), 1.5–1.0 (m, 15H), 0.86 (t, J = 6.8 Hz, 3H), 0.7 (m, 1H);
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3-((3R*,5S*,7S*)-3-Hexyl-5-(2-(4-methoxyphenyl)propan-
2-yl)-1-oxo-1,3,4,5,7,8-hexahydrobenzo[g][1,5]dioxecin-7-
yl)prop-1-en-2-yl Ethanoate (94).
To the alkyne (±)-92 (199 mg, 428 µmol) in glacial acetic acid (8 mL)
was added Na2CO3 (89 mg, 836 µmol) followed by tri-2-furyl phos-
phine (8 mg, 33 µmol), and then dichloro(p-cymene) ruthenium(II)
dimer (10 mg, 17 µmol). The reaction vessel was fitted with a reflux condenser and heated
to 60 ◦C for 30 hours. Contents were diluted with EtOAc (50 mL), washed with saturated
aqueous NaHCO3, filtered through a plug of silica gel and concentrated. The resulting crude
oil was purified via flash chromatography (10% EtOAc in hexanes eluent) to yield 61 mg of
the starting material and 127 mg of the title compound as a colorless oil (57%, 82% brsm):
1H NMR (300 MHz, CDCl3) δ 7.86 (d, J = 7.6 Hz, 1H), 7.35 (m, 4H), 7.16 (d, J = 7.4 Hz,
1H), 6.85 (d, J = 8.7 Hz, 2H), 5.22 (m, 1H), 4.82 (m, 2H), 4.12 (m, 2H), 3.79 (s, 3H), 3.69
(m, 1H), 2.31 (m, 2H), 2.19, (m, 1H), 1.96 (s, 3H), 1.92 (m, 1H), 1.63–1.56 (m, 2H), 1.40 (s,
3H), 1.30 (s, 3H), 1.2–0.85 (br m, 8H), 0.82–0.66 (m, 4H);
3-((3R*,5S*,7R*)-3-Hexyl-5-(2-(4-methoxyphenyl)propan-
2-yl)-1-oxo-1,3,4,5,7,8-hexahydrobenzo[g][1,5]dioxecin-7-
yl)prop-1-en-2-yl Ethanoate (95).
To the alkyne (±)-93 (347 mg, 728 µmol) in glacial acetic acid (15 mL)
was added Na2CO3 (154 mg, 1.46 mmol) followed by tri-2-furyl phos-
phine (14 mg, 58 µmol), and then dichloro(p-cymene) ruthenium(II)
dimer (18 mg, 29 µmol). The reaction vessel was fitted with a reflux condenser and heated
to 60 ◦C for 10 hours. Contents were diluted with EtOAc (50 mL), washed with saturated
aqueous NaHCO3, filtered through a plug of silica gel and concentrated. The resulting crude
oil was purified via flash chromatography (10% EtOAc in hexanes eluent) to yield 84 mg of
the starting material and 200 mg of the title compound as a colorless oil (51%, 67% brsm):
1H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 7.4 Hz, 1H), 7.35 (m, 4H), 7.17 (d, J = 7.1 Hz,
1H), 6.85 (d, J = 8.7 Hz, 2H), 4.87 (m, 1H), 4.80 (s, 1H), 4.60 (s, 1H), 4.27 (d, J = 14.1
Hz, 1H), 4.03 (m, 1H), 3.93 (m, 1H), 3.78 (s, 3H), 2.55 (m, 1H), 2.4–2.2 (br m, 5H), 1.66
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(m, 2H), 1.25 (br m, 15H), 0.84 (m, 4H);
(4S*,6S*)-4-Hexyl-6-(2-(4-methoxyphenyl)propan-2-yl)-
2,2,8,8-tetramethyl-3,7-dioxa-2,8-disilanonane (96).
To the syn-diol 80 (1.41 g, 4.54 mmol) in 15 mL CH2Cl2 (15 mL)
at −78 ◦C was added 2,6-lutidine (2.12. mL, 18.29 mmol), and the
mixture stirred for five minutes. To the stirring solution at −78 ◦C was added TMSOTf
(1.55 mL, 10.06 mmol) over the course of one minute. The reaction had consumed all start-
ing material by TLC analysis within five minutes, so the reaction was quenched with water
(20 mL), and the contents were extracted thrice with CH2Cl2. The combined organics were
washed twice with 1 M HCl, then brine, dried over Na2SO4, filtered, and concentrated under
reduced pressure to yield the title compound as a colorless oil (1.67 g, 81%): 1H NMR (300
MHz, CDCl3) δ 7.31 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 3.87 (s, 3H), 3.76 (m,
1H), 3.69 (m, 1H), 1.64 (m, 1H), 1.49 (m, 3H), 1.3–1.1 (m, 14H), 0.973 (dd, J = 6.9, 6.4 Hz,
3H), 0.15 (m, 18H);
Ethyl 2-(((4S*,6S*)-4-hexyl-6-(2-(4-methoxyphenyl)propan-
2-yl)-1,3-dioxan-2-yl)methyl)benzoate (97).
To a stirred solution of bis-TMS ether 96 (1.67 g, 3.69 mmol) and
aldehyde 85 (708 mg, 3.69 mmol) in CH2Cl2 (18 mL) at −78 ◦C was
added TMSOTf (67 µL, 369 µmol). The reaction stirred for five min-
utes then was quenched with pyridine (47 µL) and poured into saturated aqueous NaHCO3
and extracted thrice with CH2Cl2. The combined organics were washed with brine, dried
over Na2SO4, filtered and concentrated under reduced pressure. The resulting crude oil was
purified via flash chromatography (10% EtOAc in hexanes eluent) to yield the title com-
pound as a colorless oil (1.76 g, 99%): 1H NMR (300 MHz, CDCl3) δ 7.85 (dd, J = 7.8, 1.0
Hz, 1H), 7.4–7.3 (m, 2H), 7.3–7.2 (m, 1H), 7.22 (d, J = 8.9 Hz, 2H), 6.79 (d, J = 8.9 Hz,
2H), 4.71 (dd, J = 6.1, 4.3 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 3.5–3.3 (m, 3H),
3.22 (dd, J = 13.3, 6.2 Hz, 1H), 1.52–1.4 (m, 2H), 1.38 (t, J = 7.1 Hz, 3H), 1.35–1.15 (m,
14H), 1.2–1.0 (m, 2H), 0.89–0.80 (app t, 3H); 13C NMR (75 MHz, CDCl3) δ 167.8, 157.7,
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138.8, 138.1, 133.2, 131.2, 130.9, 130.3, 127.8, 126.3, 113.3, 101.6, 83.9, 76.6, 60.9, 55.1, 40.7,
39.9, 36.2, 31.9, 31.7, 29.3, 26.1, 25.1, 23.0, 22.7, 14.4, 14.2;
Ethyl 2-((S*)-2-((3S*,5S*)-5-hydroxy-2-(4-methoxy-
phenyl)-2-methylundecan-3-yloxy)pent-4-
ynyl)benzoate (98).
Mixed Lewis acid was prepared by addition of TiCl4 (613 µL,
5.59 mmol) to a solution of Ti(Oi-Pr)4 (545 µL, 1.86 mmol) in
CH2Cl2 (36 mL). To the acetal 97 (300 mg, 620 µmol) and al-
lenyltributyltin (553 µL, 1.86 mmol) in CH2Cl2 (12 mL) at −42 ◦C was added the mixed
Lewis acid solution in one smooth syringe-wise addition. The reaction stirred at −42 ◦C for
15 minutes then was quenched by addition of pyridine (3 mL) followed by methanol (3 mL).
Contents were poured into 100 mL 1 M HCl and extracted thrice with EtOAc. Combined
organics were washed with 1 M HCl (50 mL), then brine, dried over Na2SO4, filtered and
concentrated under reduced pressure. The resulting crude oil was purified via flash column
chromatography (10% EtOAc in hexanes eluent) to yield the title compound (227 mg, 70%):
1H NMR (300 MHz, CDCl3) δ 7.92 (d, J = 7.6 Hz, 1H), 7.5–7.28 (m, 5H), 6.81 (d, J = 8.6
Hz, 2H), 4.42–4.36 (m, 2H), 4.07 (m, 1H), 3.78–3.70 (m, 5H), 3.3 (m, 1H), 3.15 (m, 1H), 2.8
(br s, 1H), 2.4 (m, 1H), 2.10 (m, 2H), 1.45 (t, J = 7.2 Hz, 3H), 1.3 (2 singlets, 6H), 1.2–1.0
(br m, 12H), 0.85 (t, J = 7.0 Hz, 3H);
2-((S*)-2-((3S*,5S*)-5-Hydroxy-2-(4-methoxyphenyl)-
2-methylundecan-3-yloxy)pent-4-
ynyl)benzoic acid (99).
To ester 98 (190 mg, 360 µmol) in methanol/water (2:1, 10 mL)
was added lithiumhyroxide monohydrate (860 mg, 20.5 mmol).
The reaction was heated to 60 ◦C for 15 hours. The reaction
mixture was cooled to ambient temperature, acidified to pH 1 using 2 M HCl and extracted
thrice with EtOAc. The combined organics were dried over Na2SO4, filtered and concen-
trated under reduced pressure to yield the title compound as a colorless oil (175 mg, 98%):
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1H NMR (300 MHz, CDCl3) δ 7.99 (d, J = 7.6 Hz, 1H), 7.5–7.2 (m, 5H), 6.78 (d, J = 8.7
Hz, 2H), 3.86 (m, 1H), 3.8–3.6 (m, 5H), 3.2–3.1 (m, 2H), 2.35–2.25 (m, 1H), 2.1–2.0 (m, 3H),
1.7–1.5 (m, 2H), 1.4–1.0 (br m, 16H), 0.826 (t, J = 7.0 Hz, 3H);
(3S*,5S*,7S*)-3-Hexyl-5-(2-(4-methoxyphenyl)propan-2-
yl)-7-(prop-2-ynyl)-4,5,7,8-tetrahydrobenzo[g][1,5]dioxecin-
1(3H)-one (100).
To the seco-acid 99 (371 mg, 750 µmol) in THF (9 mL) at 0 ◦C
was added triethylamine (627 µL, 4.5 mmol), followed by 2,4,6-
trichlorobenzoylchloride (586 µL, 3.75 mmol). The reaction stirred at
0 ◦C for 30 minutes, and the reaction mixture was slowly poured into an ambient-temperature
solution of DMAP (916 mg, 7.5 mmol) in toluene (375 mL). The reaction stirred for 20 min-
utes and was stripped of solvent under reduced pressure. The resulting white semi-solid was
purified via flash chromatography (10% EtOAc in hexanes eluent) to yield the title com-
pound (125 mg, 35%): 1H NMR (300 MHz, CDCl3) δ 7.97 (dd, J = 7.5, 1.3 Hz, 1H), 7.5–7.3
(m, 5H), 6.90 (d, J = 8.8 Hz, 2H), 4.81 (m, 1H), 3.85 (s, 3H), 3.72 (d, J = 13.7 Hz, 1H),
3.58 (d, J = 7.2 Hz, 1H), 3.45 (m, 1H), 3.20 (dd, J = 13.7, 7.1 Hz, 1H), 2.2–2.0 (m, 3H),
1.8 (m, 2H), 1.7 (m, 1H), 1.6 (m, 1H), 1.5–1.3 (2 singlets, 6H), 1.3–1.0 (m, 8H), 0.90 (m, 3H);
3-((3S*,5S*,7R*)-3-Hexyl-5-(2-(4-methoxyphenyl)propan-
2-yl)-1-oxo-1,3,4,5,7,8-hexahydrobenzo[g][1,5]dioxecin-7-
yl)prop-1-en-2-yl Ethanoate (101).
To the alkyne (±)-100 (50 mg, 96 µmol) in glacial acetic acid (2 mL)
was added Na2CO3 (29 mg, 278 µmol) followed by tri-2-furyl phos-
phine (2.5 mg, 11 µmol), and then dichloro(p-cymene) ruthenium(II)
dimer (3 mg, 55 µmol). The reaction vessel was fitted with a reflux condenser and heated
to 60 ◦C for 6 hours, and a further 4 mol% of each dichloro(p-cymene) ruthenium(II) dimer
and tri-2-furyl phosphine were added. The reaction was nearly complete after another 12
hours, and a spatula tip’s worth of the ruthenium catalyst and phosphine ligand were added;
the reaction was complete within 10 minutes. The contents were allowed to cool to ambient
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temperature, then were filtered through a plug of silica and concentrated. The resulting
oil was purified via flash chromatography (10% EtOAc in hexanes eluent) to yield the ti-
tle compound (18 mg, 35%): 1H NMR (300 MHz, CDCl3) δ 7.88 (app d, 1H), 7.32 (m,
4H), 7.16 (m, 1H), 6.85 (d, J = 8.8 Hz, 2H), 4.76 (m, 3H), 3.80 (s, 3H), 3.6–3.51 (m, 3H),
3.2 (m, 1H), 2.3 (m, 2H), 1.92 (s, 3H), 1.6 (m, 2H), 1.48 (m, 2H), 1.27 (m, 14H), 0.8 (m, 3H);
Ethyl 2-(2-((3S*,5S*)-2-(4-methoxyphenyl)-2-methyl-5-
(4-nitrophenylcarbonyloxy)undecan-3-yloxy)pent-4-
ynyl)benzoate (102, 103).
To a solution of alcohols 88 and 89 (3.89 g, 7.44 mmol), 4-
nitrobenzoic acid (4.96 g, 29.7 mmol), and tripehenylphosphine
(9.76 g, 37.2 mmol) in toluene (135 mL) was added diisopropyl
azodicarboxylate (7.3 mL, 37.2 mmol). The reaction stirred at
ambient temperature for two hours, and the solvent was removed in vacuo. The resulting
crude amber oil was purified via flash column chromatography (10% EtOAc eluent) to yield
the title compound as a mixture of diastereomers differing at C9 (2.74 g, 56%): 1H NMR
(300 MHz, CDCl3) δ 8.4–8.1 (m, 2H), 8.0–7.8 (m, 1H), 7.5–7.1 (m, 6H), 6.9–6.7 (m, 3H),
5.0–4.8 (m, 1H), 4.5–4.3 (m, 2H), 4.0–3.7 (m, 4H), 3.6–3.4 (m, 1H), 3.3–3.0 (m, 2H), 2.4–1.7
(m, 5H), 1.5–1.0 (m, 19H), 0.9–0.7 (m, 3H);
2-((R*)-2-((3S*,5S*)-5-Hydroxy-2-(4-methoxyphenyl)-
2-methylundecan-3-yloxy)pent-4-
ynyl)benzoic acid (104).
To a mixture of the diesters 102 and 103 (2.73 g, 4.15 mmol) in
a solution of MeOH/H2O (2:1, 135 mL) was added lithium hy-
droxide monohydrate (8.79 g, 58 mmol). Reaction was warmed
to 55 ◦C for 30 hours. The contents were acidified to pH 1 using 1 M HCl and extracted thrice
with ether. The combined organics were washed with brine, dried over MgSO4, filtered and
concentrated. The resulting crude yellow oil was purified via flash column chromatography
(40% EtOAc in hexanes eluent) to yield 197 mg of the undesired (9,13-anti-, 13,15-syn-)
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isomer and 156 mg of the title compound (8%): 1H NMR (300 MHz, CDCl3) δ 8.01 (d, J =
7.8 Hz, 1H), 7.5 (m, 1H), 7.3 (m, 2H), 7.1 (d, J = 8.7 Hz, 2H), 6.7 (d, J = 8.7 Hz, 2H), 5.7
(br s, 1H), 3.9 (m, 1H), 3.78 (m, 4H), 3.6 (m, 1H), 3.4 (m, 1H), 3.3 (m, 1H), 3.1 (m, 1H),
3.0 (m, 1H), 2.4 (m, 2H), 2.1–1.8 (m, 2H), 1.6–1.5 (m, 2H), 1.5–0.7 (m, 17 H);
(3S*,5S*,7R*)-3-Hexyl-5-(2-(4-methoxyphenyl)propan-2-
yl)-7-(prop-2-ynyl)-4,5,7,8-tetrahydrobenzo[g][1,5]dioxecin-
1(3H)-one (105).
To the seco-acid 104 (88 mg, 178 µmol) in THF (3.5 mL) at 0
◦C was added triethylamine (50 µL, 356 µmol), followed by 2,4,6-
trichlorobenzoyl chloride (28 µL, 178 µmol). Reaction stirred for 45
minutes, then the contents were taken up in a syringe and added dropwise to a solution of
DMAP (217 mg, 178 µmol) in toluene (36 mL) over the course of 30 minutes. The solvent
was removed in vacuo and the resulting white paste was purified via flash column chro-
matography (10% EtOAc in hexanes eluent) to yield the title compound (68 mg, 80%) : 1H
NMR (500 MHz, C6D6) δ 7.54 (d, J = 7.3 Hz, 1H), 7.33 (d, J = 8.6 Hz, 2H), 6.99 (m, 1H),
6.91 (m, 1H), 6.90 (m, 1H), 6.83 (d, J = 8.6 Hz, 2H); 4.75 (m, 1H), 4.40 (m, 1H), 3.92 (m,
1H), 3.36 (s, 3H), 3.27 (d, J = 14 Hz, 1H), 2.5–2.4 (m, 2H), 2.4–2.3 (m, 1H), 1.82 (s, 1H),
1.74 (d, J = 15.6 Hz, 1H), 1.53 (m, 2H), 1.45 (s, 3H), 1.44 (s, 3H), 1.5–1.15 (m, 3H), 1.1–0.9
(br m, 6H), 0.86 (m, 3H);
3-((3S*,5S*,7S*)-3-Hexyl-5-(2-(4-methoxyphenyl)propan-2-
yl)-1-oxo-1,3,4,5,7,8-hexahydrobenzo[g][1,5]dioxecin-7-
yl)prop-1-en-2-yl Ethanoate (106).
To the alkyne (±)-105 (116 mg, 243 µmol) in glacial acetic acid (4.8
mL) was added Na2CO3 (51 mg, 486 µmol) followed by tri-2-furyl
phosphine (4.5 mg, 19 µmol), and then dichloro(p-cymene) ruthe-
nium(II) dimer (6 mg, 10 µmol). The reaction vessel was fitted with a reflux condenser
and heated to 60 ◦C for 22 hours. Contents were diluted with EtOAc (50 mL), washed
with saturated aqueous NaHCO3, filtered through a plug of silica gel and concentrated. The
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resulting crude oil was purified via flash chromatography (10% EtOAc in hexanes eluent) to
yield the title compound as a colorless oil (40 mg, 31%): 1H NMR (300 MHz, CDCl3) δ 7.45
(d, J = 7.3 Hz, 1H), 7.34 (m, 3H), 7.29 (m, 1H), 7.13 (d, J = 7.3 Hz, 1H), 6.83 (d, J = 8.6
Hz, 2H), 4.79 (m, 2H), 4.48 (m, 1H), 4.28 (m, 1H), 3.77 (m, 4H), 3.21 (d, J = 13.9 Hz, 1H),
2.59 (m, 1H), 2.43 (m, 1H), 2.27 ( m, 1H), 2.00 (s, 3H), 1.65 (m, 1H), 1.57 (m, 2H), 1.30 (s,
3H), 1.28 (s, 3H), 1.12 (br m, 9H), 0.82 (dd, J = 7.0, 6.5 Hz, 3H);
Ethyl 2-((S*)-2-((3S*,5R*)-5-(ethanoyloxy)-2-(4-meth-
oxyphenyl)-2-methylundecan-3-yloxy)pent-4-
ynyl)benzoate (107).
To alcohol 98 (505 mg, 0.955 mmol) in CH2Cl2 (10 mL) at 0
◦C
was added acetic anhydride (255 µL, 2.69 mmol), then TMSOTf
(10 µL, 54 µmol). The reaction stirred at 0 ◦C for one hour,
and was quenched with pyridine (10 µL). The contents were washed with 1 M HCl, then
brine. The organics were dried over MgSO4, filtered and concentrated. The resulting oil was
purified via flash column chromatography (10% EtOAc in hexanes eluent) to yield the title
compound (182 mg, 34% over 2 steps): 1H NMR (300 MHz, CDCl3) δ 7.94 (dd, J = 7.8,
1.2 Hz, 1H), 7.5–7.2 (m, 5H), 6.84 (d, J = 6.9 Hz, 2H), 4.4 (m, 2H), 4.2 (m, 1H), 3.81 (m,
4H), 3.4 (m, 2H), 3.2 (m, 1H), 2.4 (m, 2H), 2.2 (s, 1H), 2.1 (s, 3H), 1.7 (m, 2H), 1.4–1.0 (m,
16H), 0.96 (t, J = 7.3 Hz, 3H), 0.88 (t, J = 7.0 Hz, 3H);
Ethyl 2-((R*)-4-(ethanoyloxy)-2-((3S*,5R*)-5-(ethan-
oyloxy)-2-(4-methoxyphenyl)-2-methylundecan-3-
yloxy)pent-4-enyl)benzoate (108).
To the alkyne 107 (182 mg, 0.319 mmol) in glacial acetic acid
(6.4 mL) was added Na2CO3 (68 mg) followed by tri-2-furyl
phosphine (6 mg, 25 µmol), and then dichloro(p-cymene) ruthe-
nium(II) dimer (8 mg, 13 µmol). The reaction was warmed to 60 ◦C for 24 hours. A further
4 mol% of the Ru-dimer and 8 mol% of the phosphine ligand were added, and the reaction
stirred at 60 ◦C for another 24 hours. The reaction had consumed all of the starting material
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and was diluted with EtOAc and washed with saturated aqueous NaHCO3. The aqueous
layer was back-extracted with EtOAc and the combined organics were filtered through a plug
of silica gel, dried over MgSO4, filtered and concentrated. The resulting oil was purified via
flash column chromatography (10% EtOAc in hexanes eluent) to yield the title compound
(64 mg, 32%): 1H NMR (300 MHz, CDCl3) δ 7.94 (d, J = 7.7 Hz, 1H), 7.4–7.3 (m, 1H),
7.3–7.2 (m, 4H), 6.82 (d, J = 8.9 Hz, 2H), 4.86 (m, 2H), 4.36 (m, 2H), 4.2 (m, 1H), 3.80 (m,
4H), 3.43 (m, 1H), 3.24 (m, 2H), 2.4 (m, 1H), 2.3 (m, 1H), 2.12 (s, 3H), 1.98 (s, 3H), 1.41
(t, J = 7.1 Hz, 3H), 1.4–1.0 (m, 17H), 0.9–0.8 (m, 3H), 0.6 (m, 1H);
Ethyl 2-(((2R*,6S*)-6-((R*)-2-(ethanoyloxy)octyl)-4-oxo-
tetrahydro-2H-pyran-2-yl)methyl)benzoate (109).
To enol acetate 108 (29 mg, 46 µmol) in dichloroethane (3 mL)
was added 4 A˚ molecular sieves (58 mg), then NaCO3 (58 mg). To
the enol acetate was added a solution of CAN (151 mg, 276 µmol in
920 µL CH3CN). The reaction stirred for ten minutes and the contents were filtered through
a plug of silica gel. The resulting oil was purified via flash column chromatography (15%
EtOAc in toluene eluent) to yield the title compound (10 mg, 51%): 1H NMR (300 MHz,
CDCl3) δ 7.93 (dd, J = 7.9, 1.1 Hz, 1H), 7.46 (m, 1H), 7.33 (m, 2H), 4.95 (m, 1H), 4.35 (q,
J = 7.1 Hz, 2H), 3.83 (m, 1H), 3.5 (m, 1H), 3.36 (dd, J = 13.3, 4.2 Hz, 1H), 3.18 (m, 1H),
2.5–2.1 (m, 4H), 2.01 (s, 3H), 1.96 (m, 1H), 1.65 (m, 2H), 1.4–1.0 (m, 12H), 0.879 (t, J =
7.1 Hz, 3H);
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APPENDIX B
EXPERIMENTAL PROCEDURES SUPPLEMENT TO CHAPTER 3
See preface to Appendix A for standard operating procedures.
(Z)-(1-Methoxybuta-1,3-dienyloxy)trimethylsilane (112).
(Previously reported compound47) To a solution of diisopropyl amine (14 mL,
100 mmol) in THF (75 mL) at −78 ◦C was added n-BuLi (62.5 mL of a 1.6
M solution in hexanes, 100 mmol), dropwise over 15 minutes. HMPA (21 mL,
120 mmol) was added slowly, and the reaction stirred for 10 minutes. Methyl crotonate 111
(10.6 mL, 100 mmol) was added dropwise, and the reaction stirred for 30 minutes. TMSCl
(20 mL, 157 mmol) was added to the reaction mixture dropwise, and the contents stirred
for 20 minutes at −78 ◦C. The reaction was allowed to warm to ambient temperature, and
stirred for 2 hours. The solvent was evaporated under reduced pressure and replaced with
pentane (250 mL). The LiCl precipitate was filtered off, and the organics were washed with
water (3x 70 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The
resulting light yellow crude oil was distilled at 2 torr and collected at 30 ◦C to yield the title
compound (9.65 g, 56%): 1H NMR (300 MHz, CDCl3) δ 6.50 (dt, J = 17.2, 10.4 Hz, 1H),
4.86 (ddd, J = 17.2, 2.1, 0.6 Hz, 1H), 4.62 (ddd, J = 10.4, 2.2, 0.7 Hz, 1H), 4.50 (d, J = 10.3
Hz, 1H), 3.59 (s, 3H), 0.228 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 158.6, 132.4, 106.9, 80.8,
54.7, 0.678; IR (neat) 2957, 1647, 1252, 1086, 844 cm−1; MS: m/z(%): 173 (8) [C14H16O2Si+].
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Dimethyl Penta-2,3-dienedioate (114).
(Previously reported compound48) To a solution of 3-oxo-pentanedioic acid
dimethyl ester 113 (Aldrich Chemical Company, 8.62 mL, 59.7 mmol) and 2-
chloro-1,3-dimethylimidizolinium chloride (Aldrich Chemical Company, 12.12
g, 71.66 mmol) in CH2Cl2 (600 mL) at 0
◦C was added triethylamine (25 mL, 179 mmol).
The reaction warmed to ambient temperature and stirred for 90 minutes. The solvent was
removed under reduced pressure and the organics were filtered through a plug of Celite to
remove the urea solid. The resulting orange oil was purified via flash column chromatog-
raphy (CH2Cl2 eluent) to yield the title compound as a light yellow oil (8.62 g, 92%):
1H
NMR (300 MHz, CDCl3) δ 6.05 (s, 2H), 3.78 (s, 6H);
13C NMR (75 MHz, CDCl3) δ 219.5,
163.4, 91.8, 52.2; IR (neat) 3028, 2956, 1966, 1724, 1439, 1394, 1268, 1164, 1025, 817 cm−1;
MS: m/z(%): 156 (53) [C7H8O
+
4 ].
Methyl 2-Methoxy-6-(2-methoxy-2-oxoethyl)benzoate (116).
(Previously reported compound37) Silyl ketene acetal 112 (9.26 g, 53.7 mmol)
and allene 114 (7.62 g, 48.8 mmol) were dissolved in benzene (81 mL) and
heated to reflux for 20 hours. The solvent was evaporated under reduced pres-
sure and replaced with THF. Concentrated HCl (14 drops) was added and the
mixture stirred for 30 minutes. The organics were washed with brine, dried over MgSO4,
filtered and concentrated. The resulting oil was purified via flash column chromatography
(30% EtOAc in hexanes eluent) to yield a clear oil that was a two-component mixture by
TLC. To this two-component sample in DMF (30 mL) at 0 ◦C was added K2CO3 (1.63
g, 11.8 mmol) followed by iodomethane (735 µL, 11.8 mmol). The reaction stirred for 15
hours and was poured into EtOAc/1 M HCl (100 mL total). The aqueous layer was ex-
tracted thrice with EtOAc. The combined organics were washed with 1 M HCl, then brine,
dried over MgSO4, filtered and concentrated under reduced pressure to yield the title com-
pound (2.17 g, 19%): 1H NMR (300 MHz, CDCl3) δ 7.34 (t, J = 8.0 Hz, 1H), 6.9 (m, 2H),
3.90 (s, 3H), 3.85 (s, 3H), 3.69 (s, 3H), 3.67 (s, 2H); 13C NMR (75 MHz, CDCl3) δ 171.0,
167.8, 156.9, 133.1, 130.8, 123.4, 122.8, 110.3, 55.8, 52.0, 51.9, 38.8; IR (neat) 2953, 1732,
1586, 1473, 1435, 1271, 165, 1115, 1073, 1011, 760 cm−1; MS: m/z(%): 238 (39) [C12H14O5+].
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Methyl 2-Methoxy-6-(2-oxoethyl)benzoate (117).
(Previously reported compound67) To ester 116 (790 mg, 3.32 mmol) in CH2Cl2
(35 mL) at −78 ◦C was added DIBAL (3.32 mL of a 1 M solution in hexanes)
over the course of one hour. The reaction stirred for a further 45 minutes
at −78 ◦C then was quenched with saturated aqueous sodium potassium tar-
trate. The bi-phasic mixture stirred vigorously for 45 minutes. The contents were extracted
with CH2Cl2 (3x) and the combined organics were washed with water then brine, dried over
MgSO4, filtered and concentrated to yield the title compound (645 mg, 93%):
1H NMR (300
MHz, CDCl3) δ 9.69 (s, 1H), 7.37 (m, 1H), 6.86 (m, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 3.69 (m,
2H);
2-(4-Methoxyphenyl)-2-methylpropanenitrile (120).
(Previously reported compound68) To fluoroanisole 118 (Aldrich Chemi-
cal Company, 20.0 g, 158 mmol) and isobutyronitrile 119 (56.8 mL, 634
mmol) in THF (250 mL) was added KHMDS (47.4 g, 238 mmol). The
reaction was heated to reflux for 6 days, then quenched at 0 ◦C with 200 mL 1 M HCl. The
contents were extracted with EtOAc (3x 100 mL), and the combined organics were washed
with brine (400 mL), dried over MgSO4, filtered and concentrated to yield a crude brown
oil. The oil was distilled at 2 torr and the title compound was collected at 98 ◦C (26.01 g,
94%): 1H NMR (300 MHz, CDCl3) δ 7.40 (d, J = 8.7 Hz, 2H), 6.91 (d, J = 8.7 Hz, 2H),
3.82 (s, 3H), 1.71 (s, 6H); 13C NMR (75 MHz, CDCl3 δ 159.8, 133.6, 126.4, 125.0, 114.3,
55.5, 36.6, 29.4; IR (neat) 2980, 2838, 2234, 1610, 1512, 1463, 1301, 1254, 1185, 1032, cm−1;
MS: m/z(%): 175 (22) [C11H13NO
+].
2-(4-Methoxyphenyl)-2-methylpropanal (121).
(Previously reported compound69) To nitrile 120 (12.93 g, 73.7 mmol) in
CH2Cl2 (150 mL) at −78 ◦C was added DIBAL (81 mL of a 1 M solu-
tion in hexanes, 81 mmol) over the course of two hours. The reaction
stirred at −78 ◦C for an additional 45 minutes, then was quenched with 0.5 M H2SO4 (150
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mL), warmed to ambient temperature and stirred overnight. Contents were extracted with
CH2Cl2 (3x 100 mL). The combined organics were washed with saturated aqueous NaHCO3
(100 mL), then brine (100 mL), dried over MgSO4, filtered and concentrated to yield the
title compound (12.77 g, 97%): 1H NMR (300 MHz, CDCl3) δ 9.46 (s, 1H), 7.21 (d, J = 6.7
Hz, 2H), 6.92 (dd, J = 6.7 Hz, 2H), 3.82 (s, 3H), 1.45 (s, 6H); 13C NMR (75 MHz, CDCl3)
δ 201.6, 158.6, 132.9, 127.7, 114.1, 54.8, 49.4, 22.2; IR (neat) 2970, 1723, 1513, 1253, 1185,
1034 cm−1; MS: m/z(%): 178 (35) [C11H14O+2 ].
2-(4-Methoxyphenyl)-2-methylhex-5-en-3-ol (122).
(Previously reported compound69) To aldehyde 121 (10.08 g, 56.6. mmol)
in CH2Cl2 (115 mL) at −78 ◦C was added allyl magnesium bromide (62
mL of a 1 M solution in ether, 62 mmol) dropwise. The reaction stirred
at −78 ◦C for one hour, then was quenched with saturated aqueous NH4Cl and warmed
to ambient temperature. The contents were extracted with CH2Cl2 (3x 70 mL), and the
combined organics were washed with brine, dried over MgSO4, filtered and concentrated to
yield the title compound (11.84 g, 95%): 1H NMR (300 MHz, CDCl3) δ 7.32 (d, J = 8.9 Hz,
2H), 6.88 (d, J = 8.9 Hz, 2H), 5.8 (m, 1H), 5.09 (d, J = 1.0 Hz, 1H), 5.05 (d, J = 1.1 Hz,
1H), 3.81 (s, 3H), 3.64 (m, 1H), 1.9 (m, 1H), 1.6 (m, 2H), 1.34 (2 singlets, 6H); 13C NMR
(75 MHz, CDCl3) δ 157.8, 138.9, 136.5, 127.6, 117.3, 113.5, 78.5, 55.2, 41.7, 36.6, 24.5, 24.0;
IR (neat) 3481, 2970, 2835, 1611, 113, 1252, 1185 cm−1; HRMS (EI): calcd for C14H20O2
(M+) 220.1463, found 220.1462.
2-(4-Methoxyphenyl)-2-methylhex-5-en-3-yl Ethanoate (123).
To a soln of alcohol 122 (11.65 g, 52.90 mmol), triethylamine (11.1 mL,
79.4 mmol) and DMAP (648 mg, 5.3 mmol) at 0 ◦C was added acetic
anhydride (8.10 g, 79.4 mmol) dropwise. The reaction was allowed to
warm to r.t. and stirred for 120 hours. The contents were poured into 1 M HCl (100 mL),
extracted with CH2Cl2 (3x 100 mL), washed with brine (150 mL), dried over MgSO4, fil-
tered and concentrated. The resulting crude oil was purified via flash chromatography (10%
EtOAc in hexanes eluent) to yield the title compound (11.59 g, 84%): 1H NMR (300 MHz,
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CDCl3) δ 7.32 (d, J = 9.0 Hz, 2H), 6.87 (d, J = 9.0 Hz, 2H), 5.62 (m, 1H), 5.20 (dd, J =
9.6, 3.1 Hz, 1H), 4.96 (m, 1H), 4.92 (m, 1H), 3.79 (s, 3H), 2.15–2.03 (m, 2H), 2.02 (s, 3H),
1.35 (s, 3H), 1.31 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.7, 157.9, 138.2, 135.1, 127.5,
116.8, 113.5, 79.4, 55.1, 41.1, 34.9, 26.4, 23.0, 21.0; IR (neat) 2973, 1738, 1514, 1370, 1248,
1186, 1033 cm−1; HRMS (EI): calcd for C16H22O3 (M+) 262.1569, found 262.1577.
(3S*,5R*)-6-Bromo-5-hydroxy-2-(4-methoxyphenyl)-2-
methylhexan-3-yl Ethanoate (124).
To alkene 123 (288 mg, 1.10 mmol) in THF (6 mL) and water (40
µL) at 0 ◦C was added NBS (215 mg, 1.21 mmol, freshly recrys-
talized from H2O). The reaction warmed to r.t. and stirred for 20 hours. Contents were
partitioned between into 10 mL EtOAc and 10 mL of water. The aqueous phase was ex-
tracted with EtOAc (3x 10 mL). The combined organics were washed with brine (20 mL),
dried over MgSO4, filtered and concentrated. The resulting crude oil was purified via flash
chromatography (30% EtOAc in hexanes eluent) to yield a diastereomer, later shown to be
the “syn” configuration, of the title compound (739 mg, 75%): 1H NMR (300 MHz, CDCl3)
δ 7.29 (d, J = 9.0 Hz, 2H), 6.86 (d, J = 9.0 Hz, 2H), 5.09 (dd, J = 8.4, 3.3 Hz, 1H), 3.79 (s,
3H), 3.58 (m, 1H), 3.44 (dd, J = 10.2, 3.3 Hz, 1H), 3.31 (dd, J = 10.5, 5.7 Hz, 1H), 2.59 (d,
J = 5.1 Hz, 1H), 2.05 (s, 3H), 1.71–1.59 (m, 2H), 1.33 (s, 3H), 1.29 (s, 3H); 13C NMR (75
MHz, CDCl3) δ 171.8, 158.3, 137.8, 127.8, 113.9, 78.4, 69.4, 55.5, 41.5, 39.9, 36.3, 26.4, 22.9,
21.4; IR (neat) 3455, 2970, 1732, 1514, 1248, 1033 cm−1; HRMS (EI): calcd for C16H23O4Br
(M+) 358.0780, found 358.0789.
(S*)-3-(4-Methoxyphenyl)-3-methyl-1-((R*)-oxiran-2-
yl)butan-2-yl Ethanoate (125).
To bromohydrin 124 (2.55 g, 22.76 mmol) in THF (250 mL) at 0 ◦C
was added t-BuOK (2.55 g, 22.76 mmol) in t-BuOH (40 mL). The
reaction stirred for one hour and the contents were partitioned between 150 mL water and
150 mL EtOAc and the layers were separated. The aqueous layer was extracted thrice with
EtOAc, and the combined organics were washed with brine, dried over MgSO4, filtered and
77
concentrated under reduced pressure. The resulting oil was purified via flash column chro-
matography (20% EtOAc in hexanes eluent) to yield the title compound (3.08 g, 49%): 1H
NMR (300 MHz, CDCl3) δ 7.3 (m, 2H), 6.8 (m, 2H), 5.3 (m, 1H), 3.80 (s, 3H), 2.8 (m, 1H),
2.6 (m, 1H), 2.2 (m, 1H), 2.1 (s, 3H), 1.5 (m, 2H), 1.27 (2 singlets, 6H);
(3S*,5S*)-5-Hydroxy-2-(4-methoxyphenyl)-2-
methyl-8-(trimethylsilyl)oct-7-
yn-3-yl Ethanoate (126).
To trimethylsilyl acetylene (849 mg, 8.64 mmol) in ether (40
mL) at −78 ◦C was added n-BuLi (5.4 mL of a 1.6 M solution in hexanes, 8.64 mmol)
dropwise. The reaction stirred for 35 minutes, and trimethylaluminum (4.32 mL of a 2 M
solution in hexanes, 8.64 mmol) was added. The reaction warmed to −42 ◦C and stirred for
35 minutes. The reaction was cooled to −78 ◦C and epoxide 125 (1.85 g, 6.65 mmol in 5 mL
ether) was added. The reaction stirred for 15 minutes, and BF3•Et2O (1.09 mL, 8.64 mmol)
was added dropwise. The reaction stirred for 45 minutes at −78 ◦C, then was quenched with
0.5 M HCl (20 mL) and warmed to ambient temperature. The contents were diluted with
10 mL 0.5 M HCl/80 mL EtOAc, and the combined organics were washed with saturated
NaHCO3 then brine, dried over MgSO4, filtered and concentrated under reduced pressure to
yield the title compound (2.43 g, 97%): 1H NMR (300 MHz, CDCl3) δ 7.3 (m, 2H), 6.8 (m,
2H), 5.1 (m, 1H), 3.8 (s, 3H), 2.3 (m, 2H), 2.1 (s, 3H), 1.7–1.5 (m, 3H), 1.3 (2 singlets, 6H),
1.2 (m, 1H), 0.1 (s, 9H);
(3S*,5S*)-2-(4-methoxyphenyl)-2-methyloct-7-
yne-3,5-diol (127).
To TMS alkyne 126 (2.49 g, 6.61 mmol) in MeOH (66 mL) was
added K2CO3 (1.83 g, 13.22 mmol). The reaction stirred for three
hours and the contents were partitioned between NH4Cl/ether. The layers were separated,
the organics were washed with saturated NaHCO3 then brine, and the combined aqueous
layers were back-extracted with ether (6x). The organics were dried over MgSO4, filtered
and concentrated under reduced pressure. The resulting oil was purified via flash column
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chromatography (40% EtOAc in hexanes eluent) to yield the title compound (1.29 g, 74%):
1H NMR (300 MHz, CDCl3) δ 7.3 (m, 2H), 6.8 (m, 2H), 4.0–3.85 (m, 2H), 3.8 (s, 3H), 3.6
(br s, 1H), 2.4 (br s, 1H), 2.3 (m, 2H), 2.1 (s, 1H), 1.75 (m, 1H), 1.5 (m, 1H), 1.3 (2 singlets,
6H); 13C NMR (75 MHz, CDCl3) δ 158.0, 138.8, 127.7, 113.9, 81.1, 80.5, 71.3, 70.8, 55.4,
42.1, 36.3, 27.6, 24.3, 23.8;
(4S*,6S*)-4-(2-(4-methoxyphenyl)propan-2-yl)-
2,2,8,8-tetramethyl-6-(prop-2-ynyl)-3,7-dioxa-
2,8-disilanonane (128).
To diol 127 (903 mg, 3.44 mmol) in CH2Cl2 (18 mL) at 0
◦C was
added imidazole (1.03 g, 15.14 mmol). When the solid imidazole had dissolved (30 min-
utes), freshly distilled TMSCl was added. The reaction warmed to ambient temperature and
stirred for 19 hours. The reaction was quenched with 20 mL water, extracted thrice with
CH2Cl2. The combined organics were washed with 1 M HCl then brine, dried over MgSO4,
filtered and concentrated under reduced pressure to yield the title compound (1.28 g, 99%):
1H NMR (300 MHz, CDCl3) δ 7.2 (d, J = 6.7 Hz, 2H), 6.8 (d, J = 6.7 Hz, 2H), 3.80 (s, 3H),
3.68 (m, 2H), 2.2 (m, 1H), 2.1 (m, 1H), 1.9 (t, J = 2.6 Hz, 1H), 1.7–1.4 (m, 2H), 1.26 (2
singlets, 6H), 0.07 (2 singlets, 18H);
Methyl 2-Methoxy-6-(((2S*,4S*,6S*)-4-(2-(4-methoxy
phenyl)propan-2-yl)-6-(prop-2-ynyl)-1,3-dioxan-2-yl)
methyl)benzoate (129).
To bis-TMS ether 128 (584 mg, 1.55 mmol) and aldehyde 117 (323
mg, 1.55 mmol) in CH2Cl2 (8 mL) at −78 ◦C was added TMSOTf
(30 µL, .155 mmol). The reaction stirred for 2 minutes and was
quenched with pyridine (19 µL) and poured in to saturated NaHCO3. The aqueous layer
was extracted thrice with CH2Cl2, and the combined organics were washed with brine, dried
over MgSO4, filtered and concentrated under reduced pressure. The resulting oil was pu-
rified via flash column chromatography (20% EtOAc in hexanes eluent) to yield the title
compound (551 mg, 79%): 1H NMR (300 MHz, CDCl3) δ 7.26 (m, 3H), 6.91 (d, J = 7.7
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Hz, 1H), 6.8 (m, 3H), 4.67 (t, J = 4.8 Hz, 1H), 4.0–3.8 (m, 10H), 3.6 (m, 1H), 3.50 (dd,
J = 11.3, 2.2 Hz, 1H), 3.0–2.8, (m, 1H), 2.45 (ddd, J = 16.7, 5.5, 2.7 Hz, 1H), 2.27 (ddd,
J = 16.7, 7.4, 2.7 Hz, 1H), 1.96 (t, J = 2.7 Hz, 1H), 1.4 (m, 1H), 1.3–1.2 (m, 6H), 1.1 (m, 1H);
Methyl 2-(((2S*,4S*,6S*)-4-((E)-3-iodoallyl)-6-(2-(4-
methoxyphenyl)propan-2-yl)-1,3-dioxan-2-yl)methyl)-6-
methoxybenzoate (130).
To alkyne 129 (369 mg, 816 µmol) in CH2Cl2 (4 mL) was added
zirconocene hydrochloride (253 mg, 979 µmol). The reaction flask
was covered in aluminum foil and stirred for 30 minutes. Freshly
sublimed iodine (129 mg, 1.02 mmol) was added in one portion, the reaction stirred for 30
minutes and was quenched with 5 mL 20% Na2S2O3. The biphasic mixture stirred vigorously
for one hour and was partitioned between water/CH2Cl2. The aqueous layer was extracted
with CH2Cl2 and the combined organics were washed with brine, dried over MgSO4, filtered
and concentrated to yield the title compound (337 mg, 71%) : 1H NMR (300 MHz, CDCl3)
δ 7.3 (m, 3H), 6.9 (d, J = 7.3 Hz, 1H), 6.8 (m, 3H), 6.5 (m, 1H), 6.0 (d, J = 14.4 Hz, 1H),
4.6 (m, 1H), 4.0–3.7 (m, 11H), 3.5 (m, 1H), 2.8 (m, 1H), 2.2 (m, 1H), 2.1 (m, 1H), 1.28 (m,
7H), 1.1 (m, 1H);
3-Hydroxypyran-2-one (138).
(Previously reported compound61) Solid mucic acid 137 (Acros, 50.0 g, 238
mmol) and KHSO4 (50.0 g, 367 mmol) were mixed thoroughly together in a
250 mL round bottom flask. The flask was fitted with a short-path distil-
lation condenser and receiving flask. The distillation head was left open to
atmosphere in a fume hood to allow for escape of foul-smelling yellow smoke evolved during
reaction. The distilling flask was heated with an open flame (Meeker burner) so that the
solid mass melted from the top down. Even heating (allow for constant flame movement;
flask may melt!) for 25 minutes caused collection of an orange distillate (bp = 130 ◦C).
The distillate was partitioned between 100 mL water and 100 mL EtOAc and the layers
were separated. The aqueous layer was adjusted to pH 7 with 1 M NaOH and extracted
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with EtOAc (20x 20 mL) and the combined organics were dried over MgSO4, filtered and
concentrated to yield the title compound (2.93 g, 12%): 1H NMR (300 MHz, CDCl3 δ 7.17
(dd, J = 3.6, 1.8 Hz, 1H), 6.68 (dd, J = 5.4, 1.8 Hz, 1H), 6.24 (s, 1H), 6.22 (m, 1H);
Methyl 2-Hydroxy-6-(2-methoxy-2-oxoethyl)benzoate (115).
(Previously reported compound37) Allene 114 (8.37 g, 53.6 mmol) and pyrone
138 (6.62 g, 59.0 mmol) were dissolved in toluene (150 mL) and heated to
80 ◦C for 78 hours. Solvent was evaporated under reduced pressure and the
crude material was purified via flash column chromatography (30% EtOAc in
hexanes eluent) to yield the desired salicylate (11.1 g, 92%): 1H NMR (300 MHz, CDCl3) δ
11.2 (s, 1H), 7.37 (dd, J = 7.5, 0.6 Hz, 1H), 6.97 (dd, J = 7.5, 1.2 Hz, 1H), 6.73 (ddd, J =
7.5, 1.2, 0.6 Hz, 1H), 3.90 (s, 5H), 3.69 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 171.8, 171.0,
162.8, 136.5, 134.4, 123.8, 117.4, 112.1, 51.9, 51.7, 42.3; IR (neat) 2954. 1739. 1668, 1611,
1580, 1452, 1439, 1357, 1258, 1171 cm−1; HRMS (EI): calcd for C11H12O5 (M+) 224.0685,
found 224.0684.
Methyl 2-(2-Methoxy-2-oxoethyl)-6-(tosyloxy)benzoate (139).
To phenol 115 (2.10 g, 9.37 mmol) in acetone (50 mL) was added K2CO3
(2.58 g, 18.7 mmol) then tosyl chloride (1.79 g, 9.37 mmol). The reaction was
heated to reflux for six hours and then partitioned between 75 mL water/75
mL EtOAc. The contents were extracted with EtOAc (3x 50 mL), and the
combined organics were washed with brine (75 mL), dried over MgSO4, filtered and concen-
trated under reduced pressure. The resulting oil was purified via flash chromatography (30%
EtOAc in hexanes) to yield the title compound (3.17 g, 87%): 1H NMR (300 MHz, CDCl3)
δ 7.7 (m, 2H), 7.3 (m, 3H), 7.2 (m, 1H), 7.1 (m, 1H), 3.7 ( 2 singlets, 5H), 3.62 (s, 3H), 2.41
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 171.0, 165.8, 147.4, 145.8, 135.5, 132.6, 131.4, 130.0,
128.6, 127.6, 122.3, 52.5, 52.3, 39.3, 21.9; IR (neat) 2953, 1732, 1598, 1455, 1373, 1292, 1177
cm−1; HRMS (EI): calcd for C18H18O7S (M+) 378.0773, found 378.0766.
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Methyl 2-(2-Oxoethyl)-6-(tosyloxy)benzoate (140).
To ester 139 (272 mg, 702 µmol) in CH2Cl2 (10 mL) at −78 ◦C was added
DIBAL (772 µL of a 1M solution in hexanes, 772 µmol) dropwise. The reac-
tion stirred for one hour at −78 ◦C then was quenched with saturated sodium
potassium tartrate and stirred vigorously for 30 minutes. Contents were extracted with
CH2Cl2 (3x 10 mL) and the combined organics were washed with brine (20 mL), dried over
MgSO4, filtered and concentrated to yield the title compound (205 mg, 84%):
1H NMR (300
MHz, CDCl3) δ 9.63 (s, 1H), 7.65 (m, 2H), 7.3 (m, 3H), 7.1 (d, J = 7.7 Hz, 1H), 7.0 (m, 1H),
3.8 (s, 2H), 3.7 (s, 3H), 2.41 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 198.1, 165.8, 147.5, 146.0,
134.1, 132.4, 131.8, 130.3, 130.1, 128.5, 127.7, 122.5, 52.7, 48.6, 21.9; IR (neat) 1728, 1456,
1377, 1291, 1225, 1177, 1093, 911 cm−1; HRMS (EI): calcd for C17H16O6S (M+) 348.0668,
found 348.0654.
4-(4-Methoxyphenyl)-4-methylpentane-1,3-diol (141).
(Previously reported compound1) A steady stream of ozone was bub-
bled through a soln of 2-(4-methoxyphenyl)-2-methylhex-5-en-3-ol
122 (3.09 g, 14.0 mmol) in CH2Cl2 (30 mL) at −78 ◦C for 20 min.
The soln was purged with N2, then MeOH (30 mL) was added while the temperature was
maintained at − 78 ◦C. NaBH4 (2.65 g, 70.3 mmol) was added and the reaction was warmed
to 0 ◦C for 2 hours, then to r.t. for 16 h. The reaction was quenched by careful addition of
H2O (5 mL), then the solution was concentrated by removal of the majority of the solvent
under reduced pressure. The residue was dissolved in EtOAc (200 mL) and washed with
brine (2x 30 mL). The organic layer was collected, dried (MgSO4), filtered and concentrated.
The residue was purified by flash chromatography (60% EtOAc in hexanes) to yield the title
compound as a colorless oil (2.13 g, 68%): 1H NMR (300 MHz, CDCl3) δ 7.28 (dd, J = 8.4,
3.0 Hz, 2H), 6.88 (dd, J = 8.4, 3.0 Hz, 2H), 3.80 (m, 6H), 2.66 (br s, 1H), 2.21 (br s, 1H),
1.5 (m, 2H), 1.33 (s, 3H), 1.31 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 157.8, 138.8, 127.6,
113.6, 79.9, 62.3, 55.2, 41.8, 32.8, 24.1, 23.7; IR (neat) 3371, 1960, 1610, 1513, 1295, 1252,
1186, 1035 cm−1; HRMS (EI): calcd for C13H20O3 (M+) 224.1412, found 224.1402.
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Methyl 2-(((2R*,4R*)-4-(2-(4-Methoxyphenyl)propan-
2-yl)-1,3-dioxan-2-yl)methyl)-6-(tosyloxy)benzoate (142).
Diol 141 (3.21 g, 14.3 mmol) and aldehyde 140 (5.54 g, 14.3 mmol)
were dissolved in benzene (30 mL) and pTSA (272 mg, 1.43 mmol)
was added. The reaction was heated to reflux in a vessel fitted with
a Dean-Stark trap for five hours and the reaction was quenched with
10 mL saturated NaCO3. Contents were poured into 100 mL water/100 mL EtOAc, and
the layers were separated. The aqueous layer was extracted with EtOAc (3x 50 mL), the
combined organics were washed with brine (100 mL), dried over MgSO4, filtered and concen-
trated. The resulting oil was purified via flash chromatography (30% EtOAc in hexanes) to
yield the title compound (4.04 g, 51%): 1H NMR (300 MHz, CDCl3) δ 7.8 (m, 2H), 7.4 (m,
2H), 7.3–7.1 (m, 4H), 7.1 (m, 1H), 6.8 (m, 2H), 4.6 (m, 1H), 4.0 (m, 1H), 3.8 (m, 6H), 3.6
(m, 2H), 2.9 (m, 2H), 2.5 (s, 3H), 1.5 (m, 1H), 1.25 (s, 6H), 1.1 (m, 1H); 13C NMR (75 MHz,
CDCl3) δ 166.4, 157.9, 146.7, 145.7, 138.9, 137.4, 132.9, 130.4, 130.1, 128.7, 128.4, 127.9,
120.9, 113.5, 101.6, 84.5, 67.1, 55.5, 52.6, 40.9, 39.4, 26.0, 25.8, 23.2, 22.0; IR (neat) 2965,
1732, 1514, 1456, 1378, 1288, 1250 cm−1; HRMS (EI): calcd for C30H34O8S (M+) 554.1974,
found 554.1988.
Methyl 2-((S*)-2-((S*)-1-Hydroxy-4-(4-methoxyphenyl)-
4-methylpentan-3-yloxy)pent-4-ynyl)-6-(tosyloxy)benzo-
ate (143).
Mixed Lewis acid was prepared by addition of Ti(OiPr)4 (5.48
mL, 18.7 mmol) to TiCl4 (6.16 mL, 56.1 mmol) in CH2Cl2 (91
mL). To acetal 142 (3.46 g, 6.24 mmol) and allenyltributytin
(5.56 mL, 18.7 mmol) in CH2Cl2 (31 mL) at −42 ◦C was added the mixed Lewis acid solu-
tion in one smooth pour. The reaction stirred at −42 ◦C for 10 minutes, then was quenched
by addition of pyridine (30 mL) followed by MeOH (30 mL). Contents were poured into 1 M
HCl (200 mL), extracted with CH2Cl2 (3x 100 mL) and the solvent was evaporated under
reduced pressure and replaced with ether (300 mL). The ether solution stirred with KF on
Celite (12 g) for one hour, then was filtered, dried over MgSO4, filtered and concentrated.
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The resulting oil was purified via flash chromatography (40% EtOAc in hexanes) to yield
1.15 g of starting material, 1.8 g of a Friedel-Crafts product, and the title compound (456
mg, 18% brsm): 1H NMR (300 MHz, CDCl3) δ 7.8 (m, 2H), 7.5–7.2 (m, 6H), 7.0 (m, 1H),
6.8 (m, 2H), 3.8 (m, 7H), 3.7 (m, 1H), 3.5 (m, 1H), 3.1 (m, 2H), 2.8 (m, 1H), 2.5 (s, 3H), 2.2
(m, 2H), 2.1 (s, 1H), 1.8 (br s, 1H), 1.4–1.2 (m, 8H); 13C NMR (75 MHz, CDCl3) δ 166.7,
158.0, 146.8, 145.9, 139.9, 139.5, 133.1, 131.1, 130.5, 130.1, 128.7, 128.3, 120.8, 113.6, 82.1,
81.5, 71.1, 60.5, 55.5, 52.9, 42.3, 38.6, 35.0, 28.1, 23.9, 23.6, 17.8; IR (neat) 3444, 3294, 2954,
1731, 1608, 1513, 1456, 1377 cm−1; HRMS (EI): calcd for C33H38O8NaS (M+Na+) 617.2185,
found 617.2127.
Methyl 2-((S*)-2-((S*)-4-(4-methoxyphenyl)-4-methyl-
1-oxopentan-3-yloxy)pent-4-ynyl)-6-(tosyloxy)benzo-
ate (145).
To alcohol 143 (135 mg, 227 µmol) in CH2Cl2 (12 mL) was added
NaHCO3 (286 mg, 3.4 mmol) followed by the Dess-Martin perio-
dinane (289 mg, 681 µmol). The reaction stirred for 90 minutes,
and was quenched with saturated Na2S2O3. Contents were extracted with CH2Cl2 (3x 10
mL) and the combined organics were washed with brine (20 mL), dried over MgSO4, filtered
and concentrated under reduced pressure to yield the title compound (134 mg, >99%): 1H
NMR (300 MHz, CDCl3) δ 9.0 (s, 1H), 7.7 (m, 2H), 7.4–7.1 (m, 6H), 7.1 (m, 1H), 6.8 (m,
2H), 4.0 (m, 1H), 3.8 (m, 6H), 3.6 (m, 1H), 3.0 (m, 1H), 2.8 (m, 1H), 2.5 (s, 3H), 2.3 (m,
2H), 2.1 (m, 1H), 1.7 (m, 2H), 1.26 (2 singlets, 6H); 13C NMR (75 MHz, CDCl3) δ 200.7,
166.1, 158.1, 146.8, 145.8, 139.5, 138.5, 132.9, 130.7, 130.4, 128.7, 127.9, 120.8, 113.6, 81.0,
79.0, 71.1, 55.4, 52.7, 46.2, 41.9, 38.7, 27.1, 23.8, 22.7, 21.9; IR (neat) 3306, 2954, 1724,
1608, 1514, 1178, 732 cm−1; HRMS (EI): calcd for C33H36O6NaS (M+Na+) 615.2129, found
615.2009.
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Methyl 2-(((2R*,6S*)-6-((R/S)-2-(tert-Butyldimethylsil-
yloxy)pent-4-enyl)-4-oxotetrahydro-2H-pyran-2-yl)meth-
yl)-6-(tosyloxy)benzoate (151).
To enol acetate 150 (14 mg, 17µmol), 4 A˚ molecular sieves (28 mg)
and NaHCO3 (28 mg) in dichloroethane (3 mL) was added CAN
(38 mg, 69 µmol) in 1 mL CH3CN. The reaction strirred for 35 minutes and the contents
were filtered through a plug of silica gel. The solvent was evaporated under reduced pressure
and the resulting oil was purified via flash chromatography (30% EtOAc in hexanes) to yield
the title compound (4 mg, 38%): 1H NMR (300 MHz, CDCl3) δ 7.8 (m, 2H), 7.4–7.1 (m,
3H), 6.8 (m, 2H), 5.7 (m, 1H), 5.0 (m, 2H), 4.0–3.7 (m, 6H), 3.0 (m, 2H), 2.5 (s, 3H), 2.2–2.0
(m, 6H), 1.7 (s, 2H), 0.8 (m, 9H), 0.1, (m, 6H);
Methyl 2-Hydroxy-6-(2-oxoethyl)benzoate (152).
To ester 115 (8.06 g, 35.9 mmol) in CH2Cl2 (180 mL) at −78 ◦C was added,
dropwise, DIBAL (54 mL of a 1.0 M solution in hexanes). The reaction warmed
to 0 ◦C and stirred for 1 hour, at which time the reaction was quenched with
1 M HCl (200 mL). The biphasic mixture stirred vigorouslty for 1 hour. The layers were
separated and the aqueous layer was extracted with CH2Cl2 (3x 100 mL). The combined
organics were washed with water (200 mL), then brine (200 mL), dried over MgSO4, filtered
and concentrated. The resulting crude oil was purified via flash column chromatography
(30% EtOAc in hexanes eluent) to yield the title compund (5.45 g, 78%): 1H NMR (300
MHz, CDCl3) δ 11.18 (s, 1H), 9.70 (s, 1H), 7.40 (m, 1H), 6.99 (d, J = 8.4 Hz, 1H), 6.73
(d, J = 7.2 Hz, 1H), 3.94 (s, 2H), 3.91 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 199.4, 171.1,
163.5, 135.5, 135.2, 124.4, 118.2, 112.6, 52.6, 51.6; IR (neat) 3052, 2956, 1719, 1670, 1609,
1577, 1449, 1319, 1247, 1219 cm−1; MS: m/z(%): 194 (7) [C10H10O+4 ].
4-(2-(4-Methoxyphenyl)propan-2-yl)-2,2,8,8-tetramethyl-
3,7-dioxa-2,8-disilanonane (153).
To diol 141 (5.04 g, 22.5 mol) and imidazole (6.13 g, 90.0 mmol) in
CH2Cl2 (110 mL) at 0
◦C was added TMSCl (7.33 g, 8.48 mL, 67.5
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mmol) dropwise. The reaction warmed to ambient temperature and stirred for 16 hours, then
was quenced with water (100 mL). The organics were washed with 1 M HCl (100 mL), then
brine (100 mL), dried over MgSO4, filtered and concentrated to yield the title compound
(7.43 g 90%): 1H NMR (300 MHz, CDCl3) δ 7.22 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.7 Hz,
2H), 3.80 (m, 4H), 3.53 (m, 1H), 3.42 (m, 1H), 1.53 (m, 1H), 1.38 (m, 1H), 1.2 (2 singlets,
6H), 0.2 (s, 18H); 13C NMR (75 MHz, CDCl3) δ 157.9, 140.5, 128.0, 113.5, 77.9, 60.7, 55.5,
42.4, 36.1, 26.5, 23.9, 0.94, -0.14; IR (neat) 2958, 1611, 1513, 1250, 1088 cm−1;
Methyl 2-Hydroxy-6-{4-[1-(4-methoxyphenyl)-1-methylethyl]-
1,3-dioxan-2-ylmethyl}benzoate (154).
To a solution of aldehyde 152 (25 mg, 129 µmol) and bis-TMS ether 153
(48 mg (129 µmol) in CH2Cl2 (2 mL) at −78 ◦C was added TMSOTf (3
mg, 3 µL, 13 µmol. The reaction warmed to 0 ◦C and stirred for 10 min-
utes, then was quenched with pyridine (5 drops). Contents were poured
into saturated aqueous NaHCO3 (4 mL). The aqueous layer was extracted with CH2Cl2 (3x
4 mL). The combined organics were washed with brine (10 mL), dried over MgSO4, filtered
and concentrated. The resulting crude oil was purified via flash column chromatography
(40% EtOAc in hexanes eluent) to yield the title compound (49 mg, 95%): 1H NMR (300
MHz, CDCl3) δ 11.06 (s, 1H), 7.30 (m, 1H), 7.25 (d, J = 9.0 Hz, 2H), 6.89 (dd, J = 8.4,
1.2 Hz, 1H), 6.80 (m, 3H), 4.61 (dd, J = 5.1, 4.8 Hz, 1H), 4.04 (dd, J = 11.4, 4.2 Hz, 1H),
3.89 (s 3H), 3.79 (s, 3H), 3.58 (ddd, J = 12.1, 11.4, 2.4 Hz, 1H), 3.41 (dd, J = 11.4, 1.8 Hz,
1H), 3.31 (dd, J = 13.5, 5.1 Hz, 1H), 3.23 (dd, J = 13.5, 4.8 Hz, 1H), 1.57 (ddd, J = 24.0,
12.0, 5.0 Hz, 1H), 1.29 (s, 3H), 1.28 (s, 3H), 1.07 (d, J = 12.0 Hz, 1H); 13C NMR (75 MHz,
CDCl3) δ 172.0, 162.5, 157.9, 139.0, 134.2, 127.9, 124.5, 116.6, 113.4, 112.9, 102.7, 84.7, 67.2,
55.4, 52.3, 42.2, 40.9, 26.1, 25.6, 23.2; IR (neat) 2956, 2851, 1663, 1610, 1513, 1449, 1034
cm−1; MS: m/z(%): 423 (100) [C23H28O6Na+].
86
Methyl 2-Hydroxy-6-{2-[1-(2-hydroxyethyl)-2-(4-methoxy-
phenyl)-2-methylpropoxy]pent-4-ynyl}benzoate (155).
To acetal 154 (3.13 g, 7.82 mmol) and allenyltrimethylsilane (24 wt%
soln in pentane, 10.97 g, 23 mmol) in CH2Cl2 (30 mL) at −78 ◦C was
added a −78 ◦C solution of TiCl4 (4.44 g, 23.4 mmol in 20 mL CH2Cl2)
via cannula. The reaction had consumed all starting material within 10 minutes and was
quenched with pyridine (10 mL) followed by MeOH (10 mL). The quenched mixture warmed
to ambient temperature and the contents were poured into 1 M HCl (50 mL). The layers were
separated, the aqueous layer was extracted with CH2Cl2 (3x 30 mL), the combined organics
were washed with brine (50 mL), dried over MgSO4, filtered and concentrated. The resulting
crude oil was purified via flash column chromatography (30% EtOAc in hexanes eluent) to
yield the title compound (1.74 g, dr = 6.8:1, 50%): 1H NMR (300 MHz, CDCl3) δ 11.31 (s,
1H), 7.35 (dd, J = 8.1, 7.5 Hz, 1H), 6.95 (dd, J = 7.5, 0.9 Hz, 1H), 6.90 (d, J = 8.7 Hz, 2H),
6.79 (dd, J = 7.5, 0.9 Hz, 1H), 6.70 (d, J = 8.7 Hz, 2H), 3.81 (s, 3H), 3.79 (s, 3H), 3.75–3.65
(m, 2H), 3.35–3.25 (m, 2H), 2.84 (dd, J = 13.8, 9.6 Hz, 1H), 2.41 (dd, J = 4.8, 2.7 Hz, 1H),
2.06 (dd, J = 2.7, 2.4 Hz, 1H), 1.7–1.5 (m, 2H), 1.35-1.20 (m, 3H), 1.04 (s, 3H), 0.936 (s, 3H);
13C NMR (75 MHz, CDCl3) δ 172.1, 162.8, 157.7, 141.6, 140.7, 134.1, 127.4, 125.6, 116.7,
113.5, 113.1, 81.6, 81.4, 76.9, 71.0, 60.6, 55.4, 52.4, 42.2, 41.9, 34.3, 26.4, 24.0, 23.3; IR (neat)
3427, 3303, 2955, 1663, 1609, 1512, 1449, 1252 cm−1; MS: m/z(%): 463 (100) [C26H32O6Na+].
Methyl 2-{2-[1-Hydroxy-4-(4-methoxyphenyl)-4-methylpent-
an-3-yloxy]pent-4-ynyl}-6-methoxybenzoate (155a).
To phenol 155 (603 mg, 1.37 mmol) and K2CO3 (567 mg, 4.10 mmol)
in dry acetone (30 mL) was added iodomethane (389 mg, 171 µL, 2.74
mmol). The reaction was heated to reflux for 14 hours. The contents
were partitioned between water (100 mL) and EtOAc (100 mL) and
the layers were separated. The aqueous layer was extracted with EtOAc (3x 20 mL), the
combined organics were washed with brine (50 mL), dried over MgSO4, filtered and con-
centrated. The resulting oil was purified via flash column chromatography (30% EtOAc in
hexanes eluent) to yield the title compound (582 mg, 96%): 1H NMR (300 MHz, CDCl3) δ
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7.25 (dd, J = 8.1, 7.8 Hz, 1H), 7.19 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 7.5 Hz, 1H), 6.8–6.72
(m, 3H), 3.89 (s, 3H), 3.81 (s, 3H), 3.76 (s, 3H), 3.75–3.50 (m, 4H), 2.82 (d, J = 6.6 Hz, 2H),
2.42 (ddd, J = 17.0, 5.4, 2.7 Hz, 1H), 2.30 (ddd, J = 17.0, 6.9, 2.7 Hz, 1H), 2.06 (dd, J = 2.7,
2.4 Hz, 1H), 1.84 (br s, 1H), 1.6–1.5 (m, 2H), 1.19 (s, 3H), 1.15 (s, 3H); 13C NMR (75 MHz,
CDCl3) δ 168.9, 157.9, 156.7, 140.2, 137.0, 130.4, 127.7, 124.5, 123.7, 113.6, 109.5, 82.0,
81.7, 77.9, 71.1, 60.3, 56.2, 55.4, 52.6, 42.7, 38.1, 34.8, 26.4, 24.0, 23.5; IR (neat) 3538, 3289,
2952, 2837, 1727, 1584, 1513, 1470, 1267, 1073 cm−1; MS: m/z(%): 477 (100) [C27H34O6Na+].
Methyl 2-{2-[1-(2-Acetoxyethyl)-2-(4-methoxyphenyl)-
2-methylpropoxy]pent-4-ynyl}-6-methoxybenzoate (156).
To alcohol 155a (48 mg, 106 µmol) in CH2Cl2 (1 mL) was added
DMAP (1.3 mg, 10.6 µmol) then pyridine (17 mg, 17 µL, 211 µmol),
then acetic anhydride (32 mg, 30 µL, 211 µmol). The reaction
stirred at ambient temperature for 1 hour, then was partitioned
between water (20 mL) and CH2Cl2 (20 mL). The organics were washed with 1 M HCl (20
mL), then brine (20 mL), dried over MgSO4, filtered and concentrated to yield the title
compound (50 mg, 95%): 1H NMR (300 MHz, CDCl3) δ 7.29 (dd, J = 9.0, 7.8 Hz, 1H), 7.19
(d, J = 8.7 Hz, 2H), 6.88 (d, J = 7.8 Hz, 1H), 6.85–6.75 (m, 3H), 4.2–4.0 (m, 2H), 3.90 (s,
3H), 3.82 (s, 3H), 3.78 (s, 3H), 3.70 (m, 1H), 3.59 (dd, J = 7.8, 3.3 Hz, 1H), 2.86 (d, J =
6.9 Hz, 2H), 2.38 (ddd, J = 16.8, 5.4, 2.7 Hz, 1H), 2.28 (m, 1H), 2.06 (dd, J = 2.7, 2.1 Hz,
1H), 1.99 (s, 3H), 1.7–1.5 (m, 2H), 1.19 (s, 3H), 1.14 (s, 3H); 13C NMR (75 MHz, CDCl3) δ
171.1, 168.8, 158.0, 156.8, 139.8, 137.0, 130.4, 128.0, 127.7, 124.6, 123.8, 113.6, 109.5, 81.6,
81.3, 78.2, 71.2, 62.5, 56.2, 55.4, 52.5, 42.8, 38.2, 31.5, 26.7, 23.6, 21.3; IR (neat) 3286, 2953,
2838, 1734, 1584, 1513, 1471, 1250, 1074 cm−1; HRMS (EI): calcd for C29H36O7Na (M +
Na+) 519.2359, found 519.2335.
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Methyl 2-{4-Acetoxy)-2-[1-(2-acetoxyethyl)-2-(4-meth-
oxyphenyl)-2-methylpropoxy]pent-4-enyl}-6-meth-
oxybenzoate (157).
A solution of n-decyne (114 mg, 148 µL, 821 µmol), Na2CO3 (13
mg, 123 µmol), dicholoro(p-cymene)ruthenium dimer (20 mg, 33
µmol), tri-2-furyl phosphine (15 mg, 66 µmol) and acetic acid (99 mg, 94 µL, 1.64 mmol)
in toluene (10 mL) was heated to 80 ◦C for 45 minutes. Alkyne 156 (408 mg, 821 µmol) in
toluene (10 mL) was added in 10 portions. A further 2 equivalents of acetic acid (99 mg, 94
µL, 1.64 mmol) were added and the reaction stirred at 80 ◦C for 14 hours. The solvent was
evaporated and the crude solid was purified via flash column chromatography (30% EtOAc
in hexanes eluent) to yield the title compound (358 mg, 78%): 1H NMR (300 MHz, CDCl3)
δ 7.29 (t, J = 8.1 Hz, 1H), 7.12 (d, J = 9.0 Hz, 2H), 6.83 (d, J = 7.8 Hz, 1H), 6.82 (d,
J = 8.4 Hz, 1H), 6.77 (d, J = 8.7 Hz, 2H), 4.76 (2 singlets, 2H), 4.0–3.9 (m, 2H), 3.89 (s,
3H), 3.83 (s, 3H), 3.79 (s, 3H), 3.65–3.50 (m, 2H), 2.75 (dd, J = 13.8, 7.2 Hz, 1H), 2.59 (m,
2H), 2.19 (d, J = 6.6 Hz, 1H), 2.13 (s, 3H), 2.02 (s, 3H), 1.7–1.5 (m, 2H), 1.15 (s, 3H), 1.11
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 171.3, 169.2, 168.8, 157.9, 156.8, 153.6, 140.0, 137.4,
130.3, 127.7, 124.6, 123.8, 113.8, 109.4, 104.1, 80.4, 76.6, 62.6, 56.3, 55.4, 52.4, 42.5, 38.9,
38.7, 31.4, 26.5, 23.9, 21.4, 21.3; IR (neat) 2959, 2838, 1740, 1735, 1513, 1250, 1074 cm−1;
MS: m/z(%): 579 (100) [C31H40O9Na
+].
Methyl 2-{[6-(2-Acetoxyethyl)-4-oxotetrahydro-2H-pyran-2-
yl]methyl}-6-methoxybenzoate (158).
To a solution of enol acetate 157 (33 mg, 59 µmol), NaHCO3 (66 mg),
and powdered 4 A˚ molecular sieves (66 mg) in 1,2-dichloroethane (4 mL)
at 40 ◦C was added a solution of CAN (130 mg, 237 µmol) in acetonitrile
(1 mL) in one portion. The reaction turned a murky green color and stirred for 10 minutes at
40 ◦C. The contents were filtered through a plug of silica gel (EtOAc eluent), concentrated,
and purified via flash column chromatography (40% EtOAc in hexanes eluent) to yield the
title compound (16 mg, 77%): 1H NMR (300 MHz, CDCl3) δ 7.30 (m, 1H), 6.88 (d, J = 7.8
Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 4.2–4.1 (m, 2H), 4.0–3.7 (m, 7H), 3.67 (m, 1H), 2.97 (dd,
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J = 13.8, 7.2 Hz, 1H), 2.75 (dd, J = 14.1, 5.1 Hz, 1H), 2.4–2.2 (m, 4H), 2.02 (s, 3H), 2.0–1.8
(m, 2H); 13C NMR (75 MHz, CDCl3) δ 206.8, 171.3, 168.9, 156.9, 136.2, 130.7, 123.1, 109.8,
77.6, 74.0, 61.1, 56.3, 52.6, 47.9, 47.7, 40.1, 35.5, 21.3; IR (neat) 2954, 1732, 1585, 1471,
1267, 1073 cm−1; HRMS (EI): calcd for C31H24O7Na (M + Na+) 387.1420, found 387.1432.
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APPENDIX C
EXPERIMENTAL PROCEDURES SUPPLEMENT TO CHAPTER 4
See preface to Appendix A for standard operating procedures.
5-Hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (160).
(Previously reported compound70) To a solution of 2,6-dihydroxybenzoic acid
159 (32.5 g, 211 mmol), DMAP (1.30 g, 10.7 mmol) and acetone (20 mL, 280
mmol) in 1,2-dimethoxyethane (70 mL) was added SOCl2 (22 mL, 302 mmol)
dropwise. The reaction stirred for 1 hour and was purged with N2 for 2 hours
to displace HCl gas. The volatiles were evaporated under reduced pressure and the residue
was suspended in a mixture of 20 mL hexanes/20 mL CH2Cl2 and filtered through a pad of
silica (11 g). The silica was washed with a further 80 mL of the 1:1 hexanes:CH2Cl2 mixture
and then the solvent was evaporated. The residue was dissolved in hexanes (30 mL), and the
precipitate that formed was collected to yield the title compound (35.5 g, 84%): 1H NMR
(300 MHz, CDCl3) δ 10.35 (s, 1H), 7.42 (t, J = 8.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 6.45
(d, J = 8.4 Hz, 1H), 1.76 (s, 6H);
2,2-Dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl Trifluoromethane-
sulfonate (161).
(Previously reported compound71) To phenol 160 (5.74 g, 29.5 mmol) in an-
hydrous pyridine (60 mL) at 0 ◦C was added triflic anhydride (10.0 g, 5.96
mL, 35.44 mmol) dropwise. The reaction warmed to r.t. and stirred for 2
hours, whereupon it was quenched carefully with saturated aqueous NaHCO3 (60 mL). The
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aqueous layer was extracted with ether (3x 30 mL). The combined organics were dried over
Na2SO4, filtered and concentrated. Purification via flash chromatography (20% EtOAc in
hexanes eluent) yielded the title compound (11.59 g, 84%): 1H NMR (300 MHz, CDCl3) δ
7.61 (t, J = 8.4 Hz, 1H), 7.07 (dd, J = 8.4, 0.9 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 1.77 (s, 6H);
5-Allyl-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (162).
(Previously reported compound72) A soln of triflate 161 (7.31 g, 22.4 mmol),
lithium chloride (2.85 g, 67.2 mmol), palladium (tetrakis)triphenylphosphine
(1.29 g, 1.12 mmol) and allyltributyltin (8.90 g, 26.9 mmol) in THF (100 mL)
was heated to reflux for 3 hours. The reaction was quenched by addition of
water (100 mL). The aqueous layer was separated and extracted with EtOAc (3x 100 mL).
The combined organics were washed with brine (200 mL), dried over MgSO4, filtered and
concentrated. The resulting oil was purified via flash chromatography (10% EtOAc in hex-
anes eluent) to yield the title compound (4.45 g, 91%): 1H NMR (300 MHz, CDCl3) δ 7.44
(t, J = 7.9 Hz, 1H), (6.97 (d, J = 7.5 Hz, 1H), 6.85 (d, J = 8.1 Hz, 1H), 6.05 (m, 1H), 5.09
(m, 1H), 5.04 (m, 1H), 3.90 (d, J = 6.0 Hz, 2H), 1.71 (s, 6H);
2-(2,2-Dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)ethanal (163).
(Previously reported compound72) A steady stream of ozone was bubbled
through a soln of alkene 162 (3.81 g, 17.5 mmol) in CH2Cl2 (100 mL) at
0 ◦C for 20 minutes. Dimethyl sulfide (25.6 mL, 349 mmol) was added and
the reaction warmed to room temperature. Triphenylphosphine (4.58 g, 17.5
mmol) was added and the reaction stirred for 5 hours. The volatiles were evaporated under
reduced pressure and the resulting crude material was purified via flash chromatography
(30% EtOAc in hexanes eluent) to yield the title compound (3.95 g, 98%): 1H NMR (300
MHz, CDCl3) δ 9.84 (s, 1H), 7.94 (t, J = 7.9 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.90 (d, J
= 7.5 Hz, 1H), 4.22 (s, 2H), 1.73 (s, 6H);
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2-(4-Methoxyphenyl)-2-methylhex-5-en-3-yl Ethan-
oate (123).
To a soln of alcohol 122 (11.65 g, 52.90 mmol), triethylamine (11.1
mL, 79.4 mmol) and DMAP (648 mg, 5.3 mmol) at 0 ◦C was added acetic anhydride (8.10
g, 79.4 mmol) dropwise. The reaction was allowed to warm to r.t. and stirred for 120 hours.
The contents were poured into 1 M HCl (100 mL), extracted with CH2Cl2 (3x 100 mL),
washed with brine (150 mL), dried over MgSO4, filtered and concentrated. The resulting
crude oil was purified via flash chromatography (10% EtOAc in hexanes eluent) to yield the
title compound (11.59 g, 84%): 1H NMR (300 MHz, CDCl3) δ 7.32 (d, J = 9.0 Hz, 2H), 6.87
(d, J = 9.0 Hz, 2H), 5.62 (m, 1H), 5.20 (dd, J = 9.6, 3.1 Hz, 1H), 4.96 (m, 1H), 4.92 (m,
1H), 3.79 (s, 3H), 2.15–2.03 (m, 2H), 2.02 (s, 3H), 1.35 (s, 3H), 1.31 (s, 3H); 13C NMR (75
MHz, CDCl3) δ 170.7, 157.9, 138.2, 135.1, 127.5, 116.8, 113.5, 79.4, 55.1, 41.1, 34.9, 26.4,
23.0, 21.0; IR (neat) 2973, 1738, 1514, 1370, 1248, 1186, 1033 cm−1; HRMS (EI): calcd for
C16H22O3 (M
+) 262.1569, found 262.1577.
(3S*,5S*)-6-Bromo-5-hydroxy-2-(4-methoxyphenyl)-2-
methylhexan-3-yl Ethanoate (164).
To alkene 123 (288 mg, 1.10 mmol) in THF (6 mL) and water (40
µL) at 0 ◦C was added NBS (215 mg, 1.21 mmol, freshly recrystalized
from H2O). The reaction warmed to r.t. and stirred for 20 hours. Contents were partitioned
between into 10 mL EtOAc and 10 mL of water. The aqueous phase was extracted with
EtOAc (3x 10 mL). The combined organics were washed with brine (20 mL), dried over
MgSO4, filtered and concentrated. The resulting crude oil was purified via flash chromatog-
raphy (30% EtOAc in hexanes eluent) to yield a diastereomer, later shown to be the ‘anti’
configuration, of the title compound (242 mg, 24%): 1H NMR (300 MHz, CDCl3) δ 7.29 (d,
J = 8.7 Hz, 2H), 6.87 (d, J = 9.0 Hz, 2H), 5.27 (m, 1H), 3.81 (s, 3H), 3.59 (m, 1H), 3.32 (m,
2H), 3.03 (d, J = 4.5 Hz, 1H), 2.06 (s, 3H), 1.60–1.49 (m, 2H), 1.35 (s, 3H), 1.33 (s, 3H);
13C NMR (75 MHz, CDCl3) δ 172.2, 158.0, 137.8, 135.6, 127.4, 113.6, 77.8, 76.6, 67.6, 55.2,
40.9, 38.3, 35.8, 25.7, 23.7, 21.0; IR (neat) 3488, 2967, 2360, 1734, 1513, 1372, 1250, 1034
cm−1; HRMS (EI): calcd for C16H23O4Br (M+) 358.0780, found 358.0789.
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(3S*,5R*)-6-Bromo-5-hydroxy-2-(4-methoxyphenyl)-2-
methylhexan-3-yl Ethanoate (124).
To alkene 123 (288 mg, 1.10 mmol) in THF (6 mL) and water (40
µL) at 0 ◦C was added NBS (215 mg, 1.21 mmol, freshly recrystalized
from H2O). The reaction warmed to r.t. and stirred for 20 hours. Contents were partitioned
between into 10 mL EtOAc and 10 mL of water. The aqueous phase was extracted with
EtOAc (3x 10 mL). The combined organics were washed with brine (20 mL), dried over
MgSO4, filtered and concentrated. The resulting crude oil was purified via flash chromatog-
raphy (30% EtOAc in hexanes eluent) to yield a diastereomer, later shown to be the ‘syn’
configuration, of the title compound (739 mg, 75%): 1H NMR (300 MHz, CDCl3) δ 7.29 (d,
J = 9.0 Hz, 2H), 6.86 (d, J = 9.0 Hz, 2H), 5.09 (dd, J = 8.4, 3.3 Hz, 1H), 3.79 (s, 3H),
3.58 (m, 1H), 3.44 (dd, J = 10.2, 3.3 Hz, 1H), 3.31 (dd, J = 10.5, 5.7 Hz, 1H), 2.59 (d, J =
5.1 Hz, 1H), 2.05 (s, 3H), 1.71–1.59 (m, 2H), 1.33 (s, 3H), 1.29 (s, 3H); 13C NMR (75 MHz,
CDCl3) δ 171.8, 158.3, 137.8, 127.8, 113.9, 78.4, 69.4, 55.5, 41.5, 39.9, 36.3, 26.4, 22.9, 21.4;
IR (neat) 3455, 2970, 1732, 1514, 1248, 1033 cm−1; HRMS (EI): calcd for C16H23O4Br (M+)
358.0780, found 358.0789.
(S*)-3-(4-Methoxyphenyl)-3-methyl-1-[(S*)-oxiran-2-
yl]butan-2-ol (132).
To bromohydrin 164 (770 mg, 2.14 mmol) in MeOH (10 mL) at 0 ◦C
was added solid NaOMe (255 mg, 4.72 mmol) in one portion. The
reaction warmed to r.t. and stirred for 72 hours, then was quenched with saturated aqueous
amonium chloride (10 mL). Contents were partitioned between EtOAc (5 mL) and water (5
mL). The pH of the aqueous layer was adjusted to pH = 4 with 1 M HCl, and the aqueous
phase was extracted with CH2Cl2 (3x 5 mL). The combined organics were washed with brine
(10 mL), dried over MgSO4, filtered and concentrated. The resulting crude oil was purified
via flash chromatography (40% EtOAc in hexanes eluent) to yield the title compound (later
determined to be the ‘anti’ isomer, 204 mg, 40%): 1H NMR (300 MHz, CDCl3) δ 7.31 (d, J
= 8.7 Hz, 2H), 6.88 (d, J = 9.0 Hz), 2H), 3.85 (ddd, J = 10.8, 3.9, 2.1 Hz, 1H), 3.81 (s, 3H),
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3.12 (m, 1H), 2.80 (app t, J = 4.2 Hz, 1H), 2.56 (dd, J = 4.8, 2.7 Hz, 1H), 1.71 (dd, J =
4.2, 1.2 Hz, 1H), 1.64 (m, 1H), 1.48 (m, 1H), 1.32 (s, 3H), 1.31 (s, 3H); 13C NMR (75 MHz,
CDCl3) δ 158.0, 138.8, 127.9, 114.1, 77.8, 55.6, 51.2, 47.8, 42.0, 34.4, 24.8, 23.8; IR (neat)
3475, 2963, 1512, 1295 cm−1; HRMS (EI): calcd for C14H20O3 (M+) 236.1412, found 236.1412.
(S*)-3-(4-Methoxyphenyl)-3-methyl-1-[(R*)-oxiran-2-
yl]butan-2-ol (133).
To bromohydrin 124 (3.44 g, 9.58 mmol) in MeOH (50 mL) at 0 ◦C
was added solid NaOMe (1.14 g, 21.1 mmol) in one portion. The re-
action warmed to r.t. and stirred for 72 hours, then was quenched with saturated aqueous
amonium chloride (50 mL). Contents were partitioned between EtOAc (50 mL) and water
(50 mL). The pH of the aqueous layer was adjusted to pH = 4 with 1 M HCl, and the
aqueous phase was extracted with CH2Cl2 (3x 50 mL). The combined organics were washed
with brine (100 mL), dried over MgSO4, filtered and concentrated. The resulting crude oil
was purified via flash chromatography (30% EtOAc in hexanes eluent) to yield the title com-
pound (later determined to be the ‘syn’ isomer, 1.45 g, 64%): 1H NMR (300 MHz, CDCl3)
δ 7.30 (d, J = 9.0 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 3.86 (ddd, J = 10.5, 3.6, 1.8 Hz, 1H),
3.81 (s, 3H), 3.04 (m, 1H), 2.72 (app t, J = 4.2 Hz, 1H), 2.41 (dd, J = 4.8, 2.7 Hz, 1H),
2.03 (d, J = 3.6 Hz, 1H), 1.66 (ddd, J = 14.4, 4.5, 1.8 Hz, 1H), 1.39 (m, 1H), 1.34 (s, 3H),
1.31 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 157.9, 138.6, 127.5, 113.6, 78.2, 55.2, 51.7, 46.5,
41.7, 34.5, 24.5, 23.5; IR (neat) 3469, 2966, 1513, 1251, 1186 cm−1; HRMS (EI): calcd for
C14H20O3 (M
+) 236.1412, found 236.1406.
(3S*,5R*)-2-(4-Methoxyphenyl)-2-methyloct-7-ene-
3,5-diol (165).
To a solution of copper(I) iodide (62 mg, 0.324 mol) in THF (2
mL) at −78 ◦C was added a 1.0 M soln of vinyl magnesium bro-
mide (3.24 mL, 3.24 mmol), dropwise. The reaction stirred for 30 minutes at −78 ◦C, then
epoxide 132 (255 mg, 1.08 mmol) in THF (3 mL) was dropwise. The reaction warmed to
r.t. and stirred for 12 hours. The flask was cooled to 0 ◦C and the reaction was quenched
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with saturated aqueous amonium chloride (5 mL). A steady stream of compressed air was
bubbled gently through the suspension for 1.5 hours. Contents were partitioned between
water (10 mL) and EtOAc (10 mL). The aqueous layer was extracted with EtOAc (3x 10
mL). The combined organics were washed with brine (10 mL), dried over MgSO4, filtered
and concentrated. Purification by flash chromatography yielded the title compound (66 mg,
38%): 1H NMR (300 MHz, CDCl3) δ 7.32 (d, J = 8.7, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.78
(m, 1H), 5.14 (m, 1H), 5.10 (m, 1H), 3.95 (m, 2H), 3.81 (s, 3H), 2.24 (m, 2H), 2.12 (d, J =
4.2 Hz, 1H), 1.88 (d, J = 3,3 Hz, 1H), 1.50 (dd, J = 6.0, 5.7 Hz, 2H), 1.33 (s, 3H), 1.31 (s,
3H); 13C NMR (75 MHz, CDCl3) δ 157.9, 138.9, 134.9, 127.6, 118.1, 113.7, 75.9, 68.5, 55.2,
41.8, 41.7, 36.9, 24.4, 23.5; IR (neat) 3413, 2958, 1512, 1250, 1036 cm−1; HRMS (EI): calcd
for C16H24O3 (M
+) 264.1725, found 264.1712.
(3S*,5S*)-2-(4-Methoxyphenyl)-2-methyloct-7-ene-
3,5-diol (166).
To a solution of copper(I) iodide (114 mg, 0.597 mol) in THF (4
mL) at −78 ◦C was added a 1.0 M soln of vinyl magnesium bro-
mide (5.97 mL, 5.97 mmol), dropwise. The reaction stirred for 30 minutes at −78 ◦C, then
epoxide 133 (470 mg, 1.99 mmol) in THF (6 mL) was dropwise. The reaction warmed to
r.t. and stirred for 12 hours. The flask was cooled to 0 ◦C and the reaction was quenched
with saturated aqueous amonium chloride (10 mL). A steady stream of compressed air was
bubbled gently through the suspension for 1.5 hours. Contents were partitioned between
water (20 mL) and EtOAc (20 mL). The aqueous layer was extracted with EtOAc (3x 20
mL). The combined organics were washed with brine (20 mL), dried over MgSO4, filtered
and concentrated. Purification by flash chromatography yielded the title compound (364
mg, 69%): 1H NMR (300 MHz, CDCl3) δ 7.30 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz,
2H), 5.80 (m, 1H), 5.13 (m, 1H), 5.08 (m, 1H), 3.90–3.77 (m, 5H), 3.22 (br s, 1H), 2.58 (br
s, 1H), 2.20 (m, 2H), 1.58 (m, 1H), 1.39 (m, 1H), 1.33 (s, 3H), 1.30 (s, 3H); 13C NMR (75
MHz, CDCl3) δ 158.3, 139.1, 134.9, 127.9, 118.2, 114.0, 81.0, 72.4, 55.6, 42.7, 42.2, 37.1,
24.5, 23.9; IR (neat) 3379, 2964, 1513, 1297, 1073 cm−1; HRMS (EI): calcd for C16H24O3
(M+) 264.1725, found 264.1720.
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(4R*,6S*)-4-Allyl-6-[2-(4-methoxyphenyl)propan-2-
yl]-2,2-dimethyl-1,3-dioxane (167).
To diol 165 (33 mg, 0.124 mmol) in 2,2-dimethoxypropane (10 mL)
was added a catalytic amount (<5 mg) amount of p-toluenesulfonic
acid. The reaction stirred at r.t. for 24 hours. The reaction was concentrated to a volume
of <1 mL, and the contents were purified via flash chromatography (10% EtOAc in hexanes
eluent) to yield the title compound (36 mg, 96%): 1H NMR (300 MHz, CDCl3) δ 7.32 (d, J
= 9.0 Hz, 2H), 6.85 (d, J = 9.0 Hz, 2H), 5.74 (m, 1H), 5.05 (m, 1H), 5.00 (m, 1H), 3.9–3.7
(m, 4H), 3.65 (m, 1H), 2.18 (m, 1H), 2.11 (m, 1H), 1.6–1.1 (m, 14H); 13C NMR (75 MHz,
CDCl3) δ 157.5, 138.8, 134.7, 127.9, 116.5, 113.0, 100.3, 73.6, 66.8, 55.2, 40.2, 40.0, 33.6,
25.8, 24.8, 24.1, 23.2; IR (neat) 2984, 1612, 1513, 1377, 1251, 1225 cm−1; HRMS (EI): calcd
for C19H28O3 (M
+) 304.2038, found 304.2036.
(4S*,6S*)-4-Allyl-6-[2-(4-methoxyphenyl)propan-2-
yl]-2,2-dimethyl-1,3-dioxane (168).
To diol 166 (112 mg, 0.424 mmol) in 2,2-dimethoxypropane
(20 mL) was added a catalytic amount (<5 mg) amount of p-
toluenesulfonic acid. The reaction stirred at r.t. for 24 hours. The reaction was concentrated
to a volume of <1 mL, and the contents were purified via flash chromatography (10% EtOAc
in hexanes eluent) to yield the title compound (121 mg, 94%): 1H NMR (300 MHz, CDCl3)
δ 7.30 (d, J = 9.0 Hz, 2H), 6.84 (d, J = 9.0 Hz, 2H), 5.75 (m, 1H), 5.05 (m, 1H), 5.00 (m,
1H), 4.9–4.7 (m, 5H), 2.25 (m, 1H), 2.07 (m, 1H), 1.41 (s, 3H), 1.39 (s, 3H), 1.30 (s, 3H), 1.28
(s, 3H), 1.13 (m, 1H), 1.05 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 157.5, 139.0, 134.5, 127.8,
116.8, 113.1, 98.5, 76.3, 55.2, 40.9, 40.5, 31.0, 30.1, 25.9, 22.8, 19.7; IR (neat) 2989, 1612,
1513, 1378, 1249, 1111 cm−1; HRMS (EI): calcd for C19H28O3 (M+) 304.2038, found 304.2034.
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5-(((2S*,4S*,6S*)-4-Allyl-6-(2-(4-methoxyphenyl)prop-
an-2-yl)-1,3-dioxan-2-yl)methyl)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (170).
To bis-TMS ether 169 (1.14 g, 3.01 mmol) and aldehyde 163 (663
mg, 3.01 mmol) in CH2Cl2 (25 mL) at −78 ◦C was added TMSOTf
(58 µL, 0.301 mmol). The reaction stirred for 10 minutes at −78
◦C, then was quenched with pyrdine (5 mL) and poured into saturated aqueous NaHCO3
(20 mL). The aqueous layer was extracted with CH2Cl2 (3x 20 mL). The combined organics
were washed with brine (20 mL), dried over MgSO4, filtered and concentrated. Purification
by flash chromatography (10% EtOAc in hexanes eluent) yielded the title compound (738
mg, 53%): 1H NMR (300 MHz, CDCl3) δ 7.39 (app t, J = 7.9 Hz, 1H), 7.20 (d, J = 9.0 Hz,
2H), 7.03 (dd, J = 7.8, 0.9 Hz, 1H), 6.85 (dd, J = 8.4, 1.2 Hz, 1H), 6.77 (d, J = 9.0 Hz, 2H),
5.74 (m, 1H), 5.05–4.95 (m, 2H), 4.81 (dd, J = 6.3, 4.2 Hz, 1H), 3.78 (s, 3H), 3.63 (dd, J =
13.2, 3.9 Hz, 1H), 3.53 (m, 1H), 3.46 (m, 1H), 3.36 (dd, J = 13.5, 6.3, 1H), 2.28 (m ,1H),
2.12 (m, 1H), 1.69 (s, 3H), 1.68 (s, 3H), 1.25 (s, 3H), 1.23 (s, 3H), 1.2–1.1 (m, 2H); 13C NMR
(75 MHz, CDCl3) δ 160.5, 157.6, 156.7, 141.6, 138.8, 134.6, 134.2, 127.7, 127.6, 116.9, 115.7,
113.2, 112.8, 105.1, 100.6, 83.8, 76.7, 76.0, 55.1, 40.6, 40.4, 39.5, 31.1, 25.7, 25.6, 23.3; IR
(neat) 2958, 2838, 1737, 1607, 1583, 1513, 1448, 1315, 1295, 1252, 1131, 1053 cm−1; HRMS
(EI): calcd for C28H34O6 (M
+) 466.2355, found 466.2362.
5-((epi-2-((3S*,5S*)-5-Hydroxy-2-(4-methoxyphenyl)-
2-methyloct-7-en-3-yloxy)pent-4-ynyl)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (171, 172).
To acetal 170 (385 mg, 0.825 mmol) in CH2Cl2 (5 mL) was was
added a 68 wt% soln of allenyltrimethylsilane(409 mg), and the
flask was cooled to −78 ◦C. In a separate flask, a solution of
freshly distilled TiCl4 (470 mg, 2.48 mmol) in CH2Cl2 (5 mL) was cooled to −78 ◦C. The
pre-cooled TiCl4 solution was transferred via cannula to the −78 ◦C soln containing the
substrate and nucleophile. Upon completion of addition, the reaction had consumed all
starting material and was quenched by addition of pyridine (1 mL) followed by MeOH (1
98
mL). The contents were poured into 1 M HCl (10 mL) and extracted with CH2Cl2 (3x 10
mL). The combined organics were washed with brine (20 mL), dried over MgSO4, filtered
and concentrated. The resulting crude oil was purified via flash chromatography to yield the
title compound as a mixture of in separable epimers differing at C9 (323 mg, dr = 1.008:1
(as determined by separating subsequent derivatives), 77%): 1H NMR (300 MHz, CDCl3) δ
7.47.–7.35 (m, 4H), 7.2–7.15 (m, 2H), 7.1–7.0 (m, 2H), 6.9–6.75 (m, 6H), 5.8–5.6 (m, 2H),
5.1–4.9 (m, 4H), 4.35–4.25 (m, 1H), 4.0–3.9 (m, 2H), 3.9–3.8 (m, 1H), 3.8–3.7 (m, 6H), 3.7–
3.5 (m, 2H), 3.5–3.3 (m, 3H), 3.3–3.2 (m, 1H), 3.1–3.0 (m, 1H), 2.8–2.7 (m, 1H), 2.6–2.5 (m,
1H), 2.4–2.2 (m, 2H), 2.1–1.9 (m, 7H), 1.8–1.6 (m, 12H), 1.6–1.4 (m, 3H), 1.4–1.3 (m, 6H),
1.3–1.2 (m, 3H), 1.2–1.0 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 160.5, 160.3, 157.7, 157.6,
157.2, 157.1, 143.4, 142.7, 139.9, 139.7, 135.4, 135.1, 127.8, 127.5, 127.4, 127.2, 117.1, 117.0,
116.2, 116.1, 113.4, 113.3, 112.5, 112.1, 105.3, 105.2 83.5, 82.2, 81.2, 80.8, 76.7, 75.8, 75.7,
71.3, 70.9, 70.4, 69.7, 55.2, 55.1, 42.6, 42.4, 42.1, 42.0, 39.5, 39.0, 37.6, 37.5, 25.9, 25.8, 25.6,
25.5, 23.9, 23.6, 23.5, 23.3, 22.0; IR (neat) 3525, 3300, 2937, 1732, 1606, 1581, 1511, 1476,
1314, 1251, 1048 cm−1; HRMS (EI): calcd for C31H39O6 (M + H+) 507.2747, found 507.2739.
5-((R*/S*)-2-((3S*,5S*)-5-(tert-Butyldimethylsilyloxy)-
2-(4-methoxyphenyl)-2-methyloct-7-en-3-yloxy)pent-4-
ynyl)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (173).
To a solution of epimeric alcohols 171 and 172 (489 mg, 0.965
mmol) and imidazole (138 mg, 2.03 mmol) in CH2Cl2 (10 mL) was
added TBSCl (291 mg, 1.93 mmol). The reaction stirred for 48 h
and was quenched with water (10 mL). The aqueous layer was extracted with CH2Cl2 (3x
10 mL). The combined organics were washed with brine (20 mL), dried over MgSO4, filtered
and concentrated. The resulting crude oil was purified via flash chromatography (gradient
of 5% to 10% to 20% EtOAc in hexanes eluent),whereupon the diastereomers proved separa-
ble, to yield 263 mg of the higher-Rf diastereomer and 261 mg of the lower-Rf diastereomer
(87%). Spectral details for the diastereomer with higher Rf: 1H NMR (300 MHz, CDCl3)
δ 7.37 (app t, J = 7.9 Hz, 1H), 7.31 (d, J = 9.0 Hz, 2H), 7.02 (dd, J = 7.5, 0.9 Hz, 1H),
6.9–6.8 (m, 3H), 5.98 (m, 1H), 4.9–4.8 (m, 2H), 3.78 (s, 3H), 3.7–3.5 (m, 3H), 3.23 (dd, J
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= 12.0, 5.7 Hz, 1H), 3.2–3.1 (m, 1H), 2.34 (ddd, J = 16.8, 5.4, 2.7 Hz, 1H), 2.20 (m, 1H),
2.05–1.96 (m, 2H), 1.95–1.85 (m, 1H), 1.73 (s, 3H), 1.66 (s, 3H), 1.35 (m, 4H), 1.27 (s, 3H),
0.87 (m, 10H), 0.03 (s, 3H), −0.05 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.4, 157.9, 157.3,
144.2, 140.1, 135.2, 135.0, 128.3, 127.7, 116.9, 116.0, 113.5, 112.8, 105.3, 81.8, 80.7, 75.1,
70.7, 70.2, 55.6, 42.6, 42.1, 39.7, 38.8, 26.6, 26.5, 26.3, 25.5, 24.0, 23.3, 18.4, −3.8, −4.2; IR
(neat) 3309, 2954, 2932, 1736, 1607, 1582, 1513, 1476, 1297, 1253, 1080, 1044 cm−1; HRMS
(EI): calcd for C33H43O6Si (M − C4H9)+ 563.2829, found 563.2826.
5-((R*/S*)-2-((3S*,5S*)-5-(tert-Butyldimethylsilyl-
oxy)-2-(4-methoxyphenyl)-2-methyloct-7-en-3-yloxy)-
pent-4-ynyl)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (174).
To a solution of epimeric alcohols 171 and 172 (489 mg, 0.965
mmol) and imidazole (138 mg, 2.03 mmol) in CH2Cl2 (10 mL) was
added TBSCl (291 mg, 1.93 mmol). The reaction stirred for 48 h and was quenched with
water (10 mL). The aqueous layer was extracted with CH2Cl2 (3x 10 mL). The combined
organics were washed with brine (20 mL), dried over MgSO4, filtered and concentrated. The
resulting crude oil was purified via flash chromatography (gradient of 5% to 10% to 20%
EtOAc in hexanes eluent),whereupon the diastereomers proved separable, to yield 263 mg of
the higher-Rf diastereomer and 261 mg of the lower-Rf diastereomer (87%). Spectral details
for the diastereomer with lower Rf: 1H NMR (300 MHz, CDCl3) δ 7.44 (app t, J = 7.9 Hz,
1H), 7.15–7.07 (m, 3H), 6.87 (dd, J = 8.1, 0.9 Hz, 1H), 6.78 (d, J = 8.7 Hz, 2H), 5.65 (m,
1H), 5.0–4.9 (m, 2H), 3.8–3.75 (m, 4H), 3.55 (m, 1H), 3.48 (dd, J = 12.9, 4.8 Hz, 1H), 3.38
(m, 1H), 3.27 (dd, J = 12.9, 7.5 Hz, 1H), 2.58 (ddd, J = 16.8, 5.4, 2.7 Hz, 1H), 2.41 (dt, J =
16.8, 3.0 Hz, 1H), 2.23–2.13 (m, 1H), 2.04 (app t, J = 2.7, 2.4 Hz, 1H), 1.98–1.86 (m, 1H),
1.72 (s, 3H), 1.69 (s, 3H), 1.52 (m, 2H), 1.13 (s, 3H), 1.05 (s, 3H), 0.87 (s, 9H), 0.04 (s, 3H),
−0.02 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.6, 157.9, 157.4, 144.3, 140.1, 135.4, 135.1,
128.1, 127.8, 117.0, 116.2, 113.7, 112.9, 105.4, 81.8, 81.6, 71.2, 70.3, 55.6, 42.9, 42.0, 41.0,
39.6, 26.6, 26.3, 26.2, 25.8, 24.2, 23.2, 18.4, −3.7, −4.2; IR (neat) 3309, 2954, 2856, 1735,
1607, 1582, 1513, 1476, 1388, 1299, 1078, 1046 cm−1; HRMS (EI): calcd for C37H52O6Si
100
(M+) 620.3533, found 620.3535.
(R*/S*)-4-((3S*,5S*)-5-(tert-Butyldimethylsilyloxy)-2-
(4-methoxyphenyl)-2-methyloct-7-en-3-yloxy)-5-(2,2-
dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)pent-
1-en-2-yl Ethanoate (175).
A solution of n-decyne (59 mg, 77 µL, 424 µmol), Na2CO3 (7
mg, 64 µmol), dicholoro(p-cymene)ruthenium dimer (10 mg, 17
µmol), tri-2-furyl phosphine (8 mg, 34 µmol) and acetic acid (102 mg, 97 µL, 1.69 mmol)
in toluene (5 mL) was heated to 80 ◦C for 45 minutes. Alkyne 173 (263 mg, 424 µmol)
in toluene (5 mL) was added in 5 portions and the reaction stirred at 80 ◦C for 14 hours.
The solvent was evaporated and the crude solid was purified via flash column chromatogra-
phy (10% EtOAc in hexanes eluent) to yield the title compound (264 mg, 91%): 1H NMR
(300 MHz, CDCl3) δ 7.4–7.3 (m, 3H), 6.93 (dd, J = 7.5, 0.9 Hz, 1H), 6.86–6.80 (m, 3H),
5.56 (m, 1H), 4.92–4.78 (m, 4H), 3.87–3.75 (m, 5H), 3.66–3.58 (m, 1H), 3.42–3.33 (m, 1H),
3.0–2.92 (m, 1H), 2.4–2.2 (m, 2H), 2.08 (s, 3H), 1.87–1.81 (m, 1H), 1.75 (s, 3H), 1.67 (s,
3H), 1.4–1.2 (m, 7H), 1.04–0.97 (m, 1H), 0.9–0.78 (m, 10H), 0.0 (s, 3H), −0.03 (s, 3H); 13C
NMR (75 MHz, CDCl3) δ 169.4, 160.4, 157.9, 157.4, 153.7, 143.9, 140.4, 135.4, 135.1, 128.2,
127.9, 116.9, 116.2, 113.6, 112.7, 105.4, 104.6, 80.2, 75.5, 70.1, 55.6, 43.1, 41.6, 40.1, 39.9,
38.6, 27.0, 26.8, 26.3, 25.2, 23.0, 21.6, 18.4, −3.8, −4.2; IR (neat) 2954, 2931, 1755, 1735,
1607, 1513, 1252, 1203, 1079, 1042 cm−1; HRMS (EI): calcd for C35H47O8Si (M − C4H9)+
623.3040, found 623.3063.
(R*/S*)-4-((3S*,5S*)-5-(tert-Butyldimethylsilyloxy)-2-
(4-methoxyphenyl)-2-methyloct-7-en-3-yloxy)-5-(2,2-
dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)pent-
1-en-2-yl Ethanoate (176).
A solution of n-decyne (48 mg, 63 µL, 349 µmol), Na2CO3 (5.5
mg, 52 µmol), dicholoro(p-cymene)ruthenium dimer (8.5 mg, 14
µmol), tri-2-furyl phosphine (6.5 mg, 28 µmol) and acetic acid (84 mg, 80 µL, 1.40 mmol)
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in toluene (5 mL) was heated to 80 ◦C for 45 minutes. Alkyne 174 (217 mg, 349 µmol) in
toluene (5 mL) was added in 5 portions and the reaction stirred at 80 ◦C for 14 hours. The
solvent was evaporated and the crude solid was purified via flash column chromatography
(10% EtOAc in hexanes eluent) to yield the title compound (186 mg, 78%): 1H NMR (300
MHz, CDCl3) δ 7.41 (app t, J = 7.9 Hz, 1H), 7.11 (d, J = 9.0 Hz, 2H), 6.98 (m, 1H), 6.86
(dd, J = 8.1, 0.9 Hz, 1H), 6.78 (d, J = 9.0 Hz, 2H), 5.67 (m, 1H), 5.03–4.78 (m, 4H), 3.9–3.8
(m, 1H), 3.78 (s, 3H), 3.65–3.55 (m, 1H), 4.5–3.3 (m, 2H), 3.2–3.0 (m, 1H), 2.7–2.6 (m,
1H), 2.3–2.15 (m, 2H), 2.12 (s, 3H), 2.0–1.88 (m, 1H), 1.73 (s, 3H), 1.67 (s, 3H), 1.5–1.4
(m, 2H), 1.11 (s, 3H), 1.08 (s, 3H), 0.86 (s, 9H), 0.03 (s, 3H), 0.00 (s, 3H); 13C NMR (75
MHz, CDCl3) δ 169.3, 160.4, 157.9, 157.3, 153.4, 144.2, 140.3, 135.5, 134.9, 128.2, 127.8,
117.0, 116.1, 113.7, 113.0, 112.7, 105.3, 103.9, 81.0, 80.6, 77.8, 77.4, 76.9, 75.8, 70.3, 55.5,
42.8, 41.7, 40.8, 39.7, 39.3, 26.7, 26.6, 26.3, 25.4, 23.6, 21.6, 21.0, 18.5, −3.7, −4.3; IR (neat)
2954, 2931, 1737, 1607, 1582, 1513, 1314, 1253, 1210, 1076, 1046 cm−1; HRMS (EI): calcd
for C39H56O8Si (M + Na)
+ 703.3642, found 703.3604.
5-(((2R*,6S*)-6-((R*/S*)-2-(tert-Butyldimethylsilyl-
oxy)pent-4-enyl)-4-oxotetrahydro-2H-pyran-2-yl)methyl)-
2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (177).
To a solution of enol acetate 175 (264 mg, 388 µmol), NaHCO3
(250 mg), and powdered 4 A˚ molecular sieves (250 mg) in 1,2-
dichloroethane (16 mL) at 40 ◦C was added a solution of CAN (850 mg, 1.55 mmol) in
acetonitrile (4 mL) in one portion. The reaction turned a murky green color and stirred for
45 minutes at 40 ◦C. The contents were filtered through a plug of silica gel (EtOAc eluent),
concentrated, and purified via flash column chromatography (40% EtOAc in hexanes eluent)
to yield the title compound (98 mg, 52%): 1H NMR (300 MHz, CDCl3) δ 7.40 (app t, J
= 7.9 Hz, 1H), 7.00 (dd, J = 7.5, 0.6 Hz, 1H), 6.87 (dd, J = 8.4, 0.9 Hz, 1H), 5.62 (m,
1H), 4.97–4.82 (m, 2H), 3.9–3.7 (m, 2H), 3.65–3.5 (m, 2H), 3.07 (dd, J = 13.2, 8.7 Hz, 1H),
2.6–2.5 (m, 1H), 2.4–2.25 (m, 2H), 2.25–2.1 (m, 1H), 2.07–1.95 (m, 1H), 1.94–1.85 (m, 1H),
1.84–1.75 (m, 1H), 1.69 (s, 6H), 1.55 (ddd, J = 14.1, 7.8, 4.2 Hz, 1H), 0.85 (s, 9H), 0.02
(s, 6H); 13C NMR (75 MHz, CDCl3) δ 207.2, 160.9, 157.4, 143.2, 135.3, 135.2, 127.3, 117.2,
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116.4, 112.4, 105.6, 73.7, 68.8, 48.4, 47.9, 43.6, 41.2, 41.1, 26.1, 26.0, 25.9, 18.3, −4.2, −4.3;
IR (neat) 2929, 2856, 1733, 1607, 1583, 1477, 1448, 1316, 1297, 1059 cm−1; HRMS (EI):
calcd for C27H40O6NaSi (M + Na)
+ 511.2492, found 511.2472.
5-(((2R*,6S*)-6-((R*/S*)-2-(tert-Butyldimethylsilyl-
oxy)pent-4-enyl)-4-oxotetrahydro-2H-pyran-2-yl)methyl)-
2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (178).
To a solution of enol acetate 176 (209 mg, 307 µmol), NaHCO3
(200 mg), and powdered 4 A˚ molecular sieves (200 mg) in 1,2-
dichloroethane (16 mL) at 40 ◦C was added a solution of CAN (673
mg, 1.23 mmol) in acetonitrile (4 mL) in one portion. The reaction turned a murky green
color and stirred for 45 minutes at 40 ◦C. The contents were filtered through a plug of
silica gel (EtOAc eluent), concentrated, and purified via flash column chromatography (40%
EtOAc in hexanes eluent) to yield the title compound (100 mg, 67%): 1H NMR (300 MHz,
CDCl3) δ 7.42 (t, J = 7.8, 1H), 7.02 (d, J = 7.5 Hz, 1H), 6.87 (dd, J = 8.1, 0.6 Hz, 1H), 5.77
(m, 1H), 5.1–5.0 (m, 2H), 3.9–3.78 (m, 2H), 3.69–3.55 (m, 2H), 3.06 (dd, J = 12.9, 8.1 Hz,
1H), 2.50 (m, 1H), 2.35–2.25 (m, 2H), 2.25–2.14 (m, 3H), 1.75–1.63 (m, 7H), 1.44 (m, 1H),
0.78 (s, 9H), −0.12 (s, 3H), −0.33 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 207.7, 160.7, 157.4,
143.0, 135.1, 134.8, 127.5, 117.5, 116.5, 112.9, 105.5, 76.9, 73.2, 67.9, 48.5, 47.9, 44.3, 43.1,
40.9, 26.7, 26.0, 25.4, 18.2, −4.3, −5.0; IR (neat) 2953, 2930, 2856, 1734, 1606, 1583, 1477,
1381, 1318, 1299, 1269, 1213, 1079 cm−1; HRMS (EI): calcd for C23H31O6Si (M − C4H9)+
431.1890, found 431.1870.
5-(((2R*,6S*)-6-((R*/S*)-2-Hydroxypent-4-enyl)-4-oxo-
tetrahydro-2H-pyran-2-yl)methyl)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (179).
To TBS ether 177 (98 mg, 0.200 mmol) in THF (1 mL) was added
water (1 mL) followed by glacial acetic acid (3 mL). The reaction
stirred for 12 hours and was partitioned between water (10 mL) and
EtOAc (10 mL). The organics were washed with water (2x 10 mL), then saturated aqueous
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NaHCO3 (20 mL). The combined aqueous layers were back-extracted with EtOAc (3x 10
mL). The combined organics were dried over MgSO4, filtered and concentrated. Purification
via flash chromatography (50% EtOAc in hexanes eluent) yielded the title compound (56
mg, 75%): 1H NMR (300 MHz, CDCl3) δ 7.48 (app t, J = 7.9 Hz, 1H), 6.97 (dd, J = 7.5,
0.6 Hz, 1H), 6.91 (dd, J = 8.1, 0.9 Hz, 1H), 5.73 (m, 1H), 5.07 (d, J = 0.9 Hz, 1H), 5.02
(m, 1H), 4.05–3.95 (m, 1H), 3.78–3.6 (m, 3H), 3.07 (dd, J = 13.2, 8.4 Hz, 1H), 2.87 (s, 1H),
2.63–2.55 (m, 1H), 2.42–2.27 (m, 3H), 2.25–2.06 (m, 2H), 1.72 (s, 3H), 1.69 (s, 3H), 1.68–1.57
(m, 2H); 13C NMR (75 MHz, CDCl3) δ 206.1, 160.9, 157.7, 142.4, 135.9, 134.8, 126.8, 117.9,
117.1, 112.4, 105.7, 70.8, 48.2, 47.8, 42.4, 41.9, 41.4, 26.2, 25.7; IR (neat) 3523, 2926, 1728,
1606, 1583, 1479, 1317, 1299, 1270, 1208, 1061 cm−1; HRMS (EI): calcd for C21H26O6 (M+)
374.1729, found 374.1722.
5-(((2R*,6S*)-6-((R*/S*)-2-Hydroxypent-4-enyl)-4-oxo-
tetrahydro-2H-pyran-2-yl)methyl)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (180).
To TBS ether 178 (98 mg, 0.200 mmol) in THF (1 mL) was added
water (1 mL) followed by glacial acetic acid (3 mL). The reaction
stirred for 12 hours and was partitioned between water (10 mL) and
EtOAc (10 mL). The organics were washed with water (2x 10 mL), then saturated aqueous
NaHCO3 (20 mL). The combined aqueous layers were back-extracted with EtOAc (3x 10
mL). The combined organics were dried over MgSO4, filtered and concentrated. Purification
via flash chromatography (50% EtOAc in hexanes eluent) yielded the title compound (56
mg, 75%): 1H NMR (300 MHz, CDCl3) δ 7.44 (app t, J = 7.9 Hz, 1H), 6.98 (d, J = 7.5
Hz, 1H), 6.88 (dd, J = 8.4, 0.9 Hz, 1H), 5.73 (m, 1H), 5.1–5.0 (m, 2H), 3.97–3.86 (m, 1H),
3.85–3.75 (m, 2H), 3.58 (dd, J = 13.2, 3.9 Hz, 1H), 3.16 (dd, J = 13.2, 8.1 Hz, 1H), 2.53
(dd, J = 15.0, 2.4 Hz, 1H), 2.39–2.25 (m, 4H), 2.17–2.10 (m, 2H), 1.8–1.55 (m, 8H); 13C
NMR (75 MHz, CDCl3) δ 206.8, 160.8, 157.6, 142.8, 135.5, 134.9, 126.9, 118.1, 116.8, 112.5,
105.7, 76.9, 74.4, 67.9, 47.9, 47.7, 42.1, 42.0, 41.1, 26.1, 25.8; IR (neat) 3489, 2922, 1727,
1606, 1583, 1479, 1317, 1270, 1209, 1062 cm−1; HRMS (EI): calcd for C21H26O6Na (M +
Na)+ 397.1627, found 397.1651.
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